cms.bioaccessla.com

Tag: first-in-human

  • Master Best Practices for First-in-Human Studies in Costa Rica

    Master Best Practices for First-in-Human Studies in Costa Rica

    Introduction

    First-in-human (FIH) studies in Costa Rica offer a landscape rich with potential yet fraught with challenges for MedTech and Biopharma companies. With a regulatory framework shaped by Law 9234 and the oversight of the Ministry of Health, understanding compliance requirements is critical for successful study execution.

    So, how can you tap into local expertise and regulatory strategies to make your clinical trials more efficient and boost patient recruitment? This article explores best practices that not only tackle these challenges but also reveal the strategic advantages of conducting FIH studies in this vibrant Latin American market.

    Understand the Regulatory Landscape for FIH Studies in Costa Rica

    Navigating the compliance landscape for first-in-human study Costa Rica is fraught with challenges that demand careful attention. Conducting these studies requires a comprehensive understanding of the compliance framework established by the Ministry of Health (Ministerio de Salud). Central to this framework is Law 9234, which governs biomedical research involving human subjects and emphasizes patient privacy and data protection, aligning with international standards such as HIPAA. The approval process typically begins with a submission to the National Health Research Council (CONIS) for an ethical review, followed by authorization from the Ministry of Health. On average, obtaining these approvals can take between 30 to 90 days; however, these delays can hinder research timelines and increase costs due to incomplete documentation or additional requirements. Therefore, it is crucial for researchers to prepare thorough submissions.

    To ensure adherence, preparing thorough documentation that aligns with ICH-GCP standards is crucial, guaranteeing that all study protocols meet both domestic and international expectations. Working with local compliance experts can really streamline this process, providing valuable insights into specific requirements and potential challenges that may arise during the approval stages. This strategic methodology not only enables smoother navigation through the regulatory environment but also equips sponsors to take advantage of the rapid timelines and cost efficiencies that first-in-human study Costa Rica offers. Not engaging local experts can lead to unforeseen challenges that may jeopardize research efforts. By utilizing the insights and market access strategies offered by bioaccess® through its Global Trial Accelerators™, Medtech startups can effectively navigate the complexities of the research landscape in Latin America, ensuring a successful and expedited path to market. Ultimately, leveraging local expertise can be the difference between a successful study and costly delays.

    This flowchart shows the steps researchers must take to get approval for first-in-human studies. Follow the arrows to see the process from proposal submission to study initiation, and note the decision points where approvals may be granted or require revisions.

    Implement Early Feasibility Studies to Validate Concepts

    Initial feasibility assessments (EFS) are not just beneficial; they are essential for MedTech and Biopharma firms aiming to thrive in Costa Rica’s competitive landscape. In Costa Rica, conducting EFS presents unique advantages. These include:

    Together, these factors can lead to faster approvals and lower trial expenses.

    To effectively execute EFS, partnering with regional research sites skilled in early-phase studies is crucial. Partnering with regional research sites not only boosts patient recruitment but also helps navigate local regulations effectively. Moreover, insights gained from EFS can enhance submission processes, showcasing the viability of the proposed clinical strategy and potentially speeding up the approval timeline.

    Established by the FDA in 2013, the EFS Program highlights the need for detailed device procedures and safety controls to mitigate risks. In Costa Rica, adherence to ICH-GCP standards and local regulatory requirements is vital for ensuring patient safety and data integrity. By concentrating on these aspects, sponsors can improve their study frameworks and increase the chances of favorable results in future larger-scale investigations. This efficiency not only accelerates the research process but also enhances the potential for innovation in the industry. Moreover, conducting studies in Latin America can lead to savings of about $25K for each patient, enabling sponsors to reinvest those funds into additional R&D or financing milestones. By embracing these strategies, firms can position themselves for success in a rapidly evolving market.

    This flowchart illustrates the steps involved in implementing early feasibility studies. Start with conducting assessments, then see how each advantage leads to partnering with research sites, which ultimately accelerates research and innovation.

    Enhance Patient Recruitment Strategies for Efficient Trials

    Patient recruitment poses significant challenges in the first-in-human study in Costa Rica, particularly where local engagement is essential for success. By utilizing regional healthcare networks and community outreach, sponsors can significantly enhance their recruitment efforts. Collaborating with regional physicians is vital, as they can direct eligible patients straight to the study. Engaging with patient advocacy groups fosters trust and credibility, which is crucial for encouraging participation.

    Leveraging social media platforms to raise awareness about the study can also be effective, especially considering that over 3 billion individuals actively engage with these platforms each month. Additionally, offering flexible scheduling and transportation assistance can help alleviate logistical barriers that may deter participation.

    It’s essential to ensure that recruitment materials are culturally sensitive and accessible in Spanish, as this can enhance engagement with the surrounding community. By applying these methods, sponsors can achieve quicker enrollment rates, ultimately leading to more efficient execution of studies. Moreover, understanding the compliance environment, including adherence to ICH-GCP standards and approval timelines from entities such as COFEPRIS, can optimize the recruitment process and improve the overall success of studies in Costa Rica. Without addressing these recruitment challenges, the potential for groundbreaking advancements in clinical research may remain unrealized.

    The central node represents the main focus on patient recruitment, while the branches show different strategies that can help improve recruitment efforts. Each sub-branch provides specific actions or considerations related to that strategy, making it easy to see how they all connect.

    Leverage Local Clinical Trial Sites for Faster Execution

    First-in-human study Costa Rica can help overcome the significant delays often faced by first-in-human studies by utilizing local clinical research sites. With a network of pre-qualified sites, sponsors benefit from established relationships that streamline the process from protocol approval to patient enrollment. Local sites have a deep understanding of the regulatory landscape. This allows them to navigate approval processes more efficiently, often achieving regulatory compliance within 30 to 90 days, as recognized by INVIMA.

    Additionally, these locations provide access to diverse patient groups. This enhances the generalizability of study outcomes and boosts recruitment rates. Indeed, research shows that 89% of investigative sites activated for Phase II and III global studies commenced enrollment, demonstrating the effectiveness of regional engagement.

    By collaborating with regional sites, sponsors can also significantly lower operational expenses, reducing travel and logistical costs linked to carrying out trials in remote areas, with possible reductions of up to 30% compared to US trials.

    To truly benefit from local engagement, sponsors should conduct thorough site assessments, considering criteria such as infrastructure, expertise, and compliance with ICH-GCP standards. This guarantees that chosen locations can efficiently meet the specific needs of first-in-human study Costa Rica and enable FDA-bridgeable data acceptance for submission purposes.

    Moreover, bioaccess® offers valuable insights into market access strategies and compliance updates, further improving the efficiency of studies in the region.

    This flowchart outlines the steps sponsors can take to effectively leverage local clinical trial sites. Each box represents a key action or benefit, and the arrows show how these steps connect to create a streamlined process for conducting trials.

    Integrate Regulatory Strategies with Clinical Execution for Success

    To achieve success in the first-in-human study Costa Rica, a strategic approach is essential. This requires a comprehensive compliance plan aligned with the clinical research protocol from the outset. Sponsors should engage regulatory experts early in the process to identify potential challenges and streamline submissions to authorities such as ANVISA in Brazil and INVIMA in Colombia. Grasping the specific compliance requirements, such as ICH-GCP standards, and the submission pathways for each authority can significantly enhance the efficiency of execution.

    For instance, ANVISA mandates a comprehensive dossier that encompasses trial data and safety information, while INVIMA has its own collection of documentation and timelines that must be adhered to. Consistent communication between medical teams and compliance affairs ensures timely updates on policy changes and guarantees that all study activities remain in line with local laws.

    Implementing electronic data capture (EDC) systems is vital for robust data management and reporting, facilitating compliance. By fostering a collaborative environment between regulatory and clinical teams, sponsors can enhance the efficiency of trial execution and improve the likelihood of successful outcomes, unlocking the full potential of clinical trials in this dynamic region.

    This flowchart outlines the steps needed to successfully integrate regulatory strategies with clinical execution. Follow the arrows to see how each step connects and builds on the previous one, ensuring a smooth process for clinical trials.

    Conclusion

    The complexities of first-in-human studies in Costa Rica present both challenges and significant opportunities for MedTech and Biopharma companies. Understanding the regulatory landscape is crucial. Implementing early feasibility studies and enhancing patient recruitment strategies can help. Leveraging local clinical trial sites and integrating regulatory strategies with clinical execution allows sponsors to accelerate their research timelines and reduce operational costs. The alignment of these best practices is essential for maximizing the potential of clinical trials in this dynamic region.

    Key insights from the article emphasize the importance of thorough documentation and compliance with local regulations, such as ICH-GCP standards, to ensure ethical and efficient study execution. Working with local experts and forming partnerships with research sites can really help speed up the approval process, enhance patient recruitment, and ultimately lead to faster, more cost-effective trials. Moreover, understanding the specific submission pathways and approval timelines from authorities like INVIMA and ANVISA enables sponsors to navigate the regulatory landscape with confidence.

    By embracing these strategies, companies not only enhance their chances of success but also contribute to the evolution of clinical research in Latin America. By leveraging speed, cost efficiency, and effective recruitment strategies, companies can unlock groundbreaking advancements in clinical research, paving the way for innovative medical solutions that benefit patients globally.

    Frequently Asked Questions

    What is the regulatory framework for conducting first-in-human studies in Costa Rica?

    The regulatory framework for first-in-human studies in Costa Rica is governed by Law 9234, which emphasizes patient privacy and data protection in line with international standards like HIPAA. Researchers must submit their studies to the National Health Research Council (CONIS) for ethical review, followed by obtaining authorization from the Ministry of Health.

    How long does the approval process typically take for FIH studies in Costa Rica?

    The approval process for first-in-human studies in Costa Rica generally takes between 30 to 90 days. Delays can occur due to incomplete documentation or additional requirements, which can hinder research timelines and increase costs.

    What are the key compliance requirements for FIH studies in Costa Rica?

    Key compliance requirements include preparing thorough documentation that aligns with ICH-GCP standards and ensuring that all study protocols meet both domestic and international expectations.

    Why is it important to work with local compliance experts in Costa Rica?

    Engaging local compliance experts can streamline the approval process by providing valuable insights into specific regulatory requirements and potential challenges. This can help researchers navigate the regulatory environment more effectively and avoid unforeseen issues that may jeopardize their studies.

    What are the advantages of conducting early feasibility studies (EFS) in Costa Rica?

    Conducting early feasibility studies in Costa Rica offers several advantages, including expedited patient recruitment, streamlined regulatory pathways, and significant cost savings, which can lead to faster approvals and lower trial expenses.

    How can partnering with regional research sites enhance EFS execution in Costa Rica?

    Partnering with regional research sites skilled in early-phase studies can boost patient recruitment and facilitate navigation through local regulations. Insights gained from EFS can also improve submission processes and showcase the viability of clinical strategies, potentially speeding up approval timelines.

    What is the significance of adhering to ICH-GCP standards in clinical trials?

    Adhering to ICH-GCP standards is vital for ensuring patient safety and data integrity in clinical trials. It helps sponsors improve their study frameworks and increases the chances of favorable results in future larger-scale investigations.

    How can conducting studies in Latin America lead to cost savings for sponsors?

    Conducting studies in Latin America can save sponsors approximately $25,000 for each patient, allowing them to reinvest those funds into additional research and development or financing milestones, thereby enhancing their operational efficiency in a competitive market.

    List of Sources

    1. Understand the Regulatory Landscape for FIH Studies in Costa Rica
      • linkedin.com (https://linkedin.com/pulse/navigating-clinical-research-regulations-costa-rica-soto-md-msc–lls6e)
      • thecostaricanews.com (https://thecostaricanews.com/costa-rica-moves-forward-in-consolidating-an-efficient-regulatory-system-to-ensure-the-quality-of-medicines-and-health-technologies)
      • qreg.co.uk (https://qreg.co.uk/costa-rica-regulatory-requirements)
    2. Implement Early Feasibility Studies to Validate Concepts
      • starfishmedical.com (https://starfishmedical.com/resource/fda-early-feasibility-studies-program)
      • How does an Early Feasibility Study differ from a Pivotal Study? | MED Institute (https://medinstitute.com/blog/how-does-an-early-feasibility-study-differ-from-a-pivotal-study)
      • jacc.org (https://jacc.org/doi/10.1016/j.jacc.2020.10.019)
    3. Enhance Patient Recruitment Strategies for Efficient Trials
      • Seven Best Practices For Clinical Trial Patient Recruitment (https://openclinica.com/blog/seven-patient-recruitment-best-practices-used-by-leading-research-studies)
      • Patient Recruitment for Clinical Trials: Strategies That Actually Work (https://kapsuletech.com/blog/patient-recruitment-clinical-trials)
      • 25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)
      • 2025 Trends In Patient Recruitment: From Disruption To Precision (https://clinicalleader.com/doc/trends-in-patient-recruitment-from-disruption-to-precision-0001)
      • SCIRP Open Access (https://scirp.org/journal/paperinformation?paperid=128354)
    4. Leverage Local Clinical Trial Sites for Faster Execution
      • 25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)
      • hclinical.com (https://hclinical.com/what-are-the-benefits-of-conducting-clinical-research-in-latin-america)
      • Latin America: A Compelling Region To Conduct Your Clinical Trials (https://clinicalleader.com/doc/latin-america-a-compelling-region-to-conduct-your-clinical-trials-0001)
      • Enrollment Performance: Weighing the “Facts” | Applied Clinical Trials Online (https://appliedclinicaltrialsonline.com/view/enrollment-performance-weighing-facts)
      • Statistical Challenges with Site Enrollment in Clinical Trials  | Rho (https://rhoworld.com/statistical-challenges-with-site-enrollment-in-clinical-trials)

  • 5 Questions Every MedTech Team Asks Before Running Their First-in-Human Trial in Latin America

    On May 8, 2026, 98 MedTech professionals from 17 countries joined our Friday In Focus webinar on running first-in-human (FIH) clinical trials in Latin America. 59% stayed past 46 minutes in a 62-minute session — and they didn’t ask curiosity questions. They asked execution questions: country selection, ethics, FDA acceptability, statistical power, step-by-step playbooks for medical device sponsors who are actively planning their first FIH outside the United States.

    If you’re evaluating whether to run your next first-in-human study in Latin America, here are the five questions your peers pushed hardest on — and how to think about each one before you commit to a country, an ethics committee, or an FDA submission strategy.

    1. Which country in Latin America is the easiest?

    This was the first question out of the gate, asked by Rocío Paublete (Sweden, PMCF & Clinical Investigation Project Manager) and echoed throughout the chat. The honest answer is: it depends on what you’re optimizing for.

    “Easy” decomposes into three orthogonal dimensions:

    • Patient recruitment speed — how quickly you can enroll the first 5–30 patients for an FIH or early feasibility study. Colombia, Mexico, and Brazil typically lead here because of dense urban hospital networks and high physician engagement with research.
    • Ethics committee turnaround — how long the IRB/CEI review cycle takes from submission to approval. Chile and Costa Rica run faster review cycles than Brazil, where amendments through CONEP can stretch.
    • Regulatory authority predictability — INVIMA (Colombia), ANVISA (Brazil), COFEPRIS (Mexico), ANMAT (Argentina), DIGEMID (Peru), and ISP (Chile) all have different timelines, fee structures, and documentation expectations.

    For most US-headquartered MedTech sponsors running an FIH, the practical sweet spot is Colombia or Costa Rica for first-patient-in speed, with Brazil considered when the indication requires larger patient diversity or when the eventual commercial path runs through Latin America’s largest market.

    2. Are those countries easier because of recruitment, or because of ethics committees?

    Rocío came back with this follow-up — and it’s the right one to ask. The two drivers behave differently:

    • Recruitment speed is largely a function of investigator network density, hospital infrastructure, and patient population. It’s a relatively stable property of the country and the indication.
    • Ethics committee speed varies by which committee, not just which country. A Bogotá-based academic medical center’s CEI that meets often may turn around sooner; a regional committee that meets less often might take much longer. The same country can deliver dramatically different timelines depending on site selection.

    The implication for sponsors: pick countries where both the recruitment and the committee math work, then pick sites where you’ve already mapped CEI cycle times empirically. Don’t optimize one without the other.

    3. Will the FDA accept clinical data generated in Latin America?

    This question, from Bhavik Gondaliya (Germany, RA), is the one that gates every conversation about whether LatAm FIH data will actually contribute to a US regulatory submission. The short answer: yes, with conditions.

    The FDA’s longstanding position on foreign clinical data is codified in 21 CFR 814.15 for PMA submissions and in 21 CFR 812.28 (subpart B) for IDE and marketing submissions, and is described on FDA’s official page, Acceptance of Data from Clinical Investigations for Medical Devices (the 2018 guidance “Acceptance of Clinical Data to Support Medical Device Applications and Submissions”). LatAm data is acceptable if:

    • The study was conducted in accordance with Good Clinical Practice (GCP), including independent ethics review and informed consent
    • The data are applicable to the US patient population (the FDA looks for population overlap on the relevant clinical and demographic axes)
    • The site investigators were qualified, the protocol was scientifically sound, and the data are auditable by FDA inspectors

    For most early-stage MedTech sponsors, the practical playbook is to design the LatAm FIH so that its protocol, endpoints, and case report forms look like what an FDA reviewer would expect to see in a US pivotal study. Doing this work upfront makes the eventual bridging to a US IDE or 510(k)/De Novo dramatically smoother.

    4. How do you handle the ethics of providing investigational therapy “for free” in lower-resource settings?

    Nyerngoor Korda Hewitt (UK, Director of Regulatory Affairs and Quality) raised this — and it’s a question every sponsor should be ready for. The concern is real: when an FIH protocol provides expensive investigational therapy at no cost in a country where standard care is often unaffordable, you can create undue inducement.

    The frameworks that govern this are well-established — the Declaration of Helsinki (especially Articles 19–20 on vulnerable populations), the Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, and country-specific implementations. Operationally, robust sponsors design their LatAm FIH protocols to address inducement directly:

    • Post-trial access — explicit commitments about whether participants will continue to receive the therapy after the trial ends, and under what conditions
    • Standard-of-care arms — when ethically and statistically appropriate, designing comparator arms so participants aren’t forced to choose between trial enrollment and accessible care
    • Independent ethics review in the host country, with documented review of the inducement question by the local CEI
    • Community engagement — particularly for indications where the trial may shape future access in the country

    The audience response on this question made clear: it’s a topic experienced sponsors and their RA teams take seriously, and one ethics committees in Colombia, Mexico, Chile, and elsewhere actively probe.

    5. Step-by-step: I have a de novo medical device and I want to do FIH in Panama or Bolivia. What does it actually look like?

    This question, from Joseph Skraba (University of Texas at Austin, Manager of Medical Device Commercialization), was the most operational of the session. Here’s the compressed playbook for a de novo Class II/III medical device sponsor:

    1. Pre-clinical foundation — bench testing, biocompatibility (ISO 10993), sterilization validation, and animal study data sufficient to support first human exposure. This is non-negotiable.
    2. FDA pre-submission (Q-Sub) is optional but strongly recommended — even for studies conducted entirely outside the US, a Q-Sub conversation aligns the FDA’s expectations for how the foreign data will support a future US submission. This is “free insurance” for your eventual regulatory path.
    3. Export approval — for a non-US-cleared device, you’ll need an FDA Export Certificate (typically a Certificate to Foreign Government, CFG) under Section 801(e) of the FD&C Act. Lead time is usually 4–6 weeks.
    4. In-country regulatory approval — country-specific medical device authorization. INVIMA (Colombia) and ANMAT (Argentina) have streamlined pathways for clinical investigation devices; smaller markets like Panama and Bolivia rely on Ministry of Health approvals that vary in predictability. Plan 8–16 weeks.
    5. Ethics committee review — single-site or multi-site CEI approval. Allow 4–12 weeks depending on country and committee. Many sponsors run this in parallel with regulatory.
    6. Site activation — investigator agreements, indemnification (and clinical trial insurance — required in most LatAm countries), training on the IFU and protocol, IRT/EDC system rollout.
    7. First-patient-in — typically 6–9 months from kickoff for a well-prepared sponsor, faster with an experienced in-country CRO.

    The realistic end-to-end timeline from contracting to first-patient-in is 6–9 months for sponsors who arrive prepared, longer for sponsors who try to compress pre-clinical or skip the FDA Q-Sub.

    Bonus: “Statistical power with 5 patients?”

    Stephanie Grassmann (Switzerland, MedTechXperts LLC) lobbed this one in — and the answer is: FIH studies aren’t powered for inferential statistics, and that’s by design.

    An FIH/early-feasibility study (typically 5–30 patients) is designed to evaluate safety, device handling, procedural success, and preliminary signals of efficacy. The endpoints are descriptive: rates, intervals, mean changes from baseline. The next study (pilot or pivotal, often 50–300+ patients) is where powered hypothesis testing begins. The two studies serve different scientific purposes and are evaluated by the FDA on different criteria.

    For sponsors evaluating whether their LatAm FIH will “count” toward their eventual US submission: it counts if it answers the questions a 5–30 patient study is designed to answer. Don’t try to make it carry weight it wasn’t designed to bear.

    Who was in the room

    The 98 attendees came from 17 countries across North America, Europe, Latin America, and Asia, with roles ranging from Regulatory Affairs leaders and Quality directors to MedTech founders and CEOs. The session ran from 11:00 AM to 12:02 PM ET on Friday, May 8, 2026, and 20% of listeners stayed for the final two minutes — an engagement signal that tracks with the seriousness of the questions asked.

    Next steps for your team

    If your team is actively planning a first-in-human study and wrestling with any of the questions above, here’s how to move forward:

    • Free 30-minute feasibility screen — share your indication, target patient count, and target FPI date, and we’ll tell you which 2–3 LatAm countries are realistic for your specific case. Book a call →
    • Read the case studies — bioaccess® has supported FIH and early-feasibility studies for cardiology, neurology, ophthalmology, and orthopedic device sponsors across Colombia, Mexico, Chile, Costa Rica, and Brazil. See recent case studies →
    • Stay current — we publish new analyses of LatAm regulatory shifts (ANVISA’s 2026–2027 international convergence agenda, FDA’s December 2025 RWE guidance and what it means for LatAm data, ophthalmic FIH dynamics in smaller markets) every week. Subscribe via the form below.

    Thanks to the 98 MedTech professionals who joined the session, and to the panelists and moderators who made the depth of the discussion possible. The next Friday In Focus session will be announced shortly.

  • Best Practices for FIH Clinical Trials in Colombia: Key Strategies

    Best Practices for FIH Clinical Trials in Colombia: Key Strategies

    Introduction

    Navigating the regulatory landscape of first-in-human (FIH) clinical trials in Colombia can be daunting, yet it presents unique opportunities for sponsors in MedTech, Biopharma, and Radiopharmaceutical sectors. With the National Food and Drug Surveillance Institute (INVIMA) overseeing a regulatory framework that promises expedited approval timelines, understanding the nuances of compliance can significantly enhance trial success.

    So, how can sponsors effectively leverage:

    • Early feasibility studies
    • Patient recruitment strategies
    • Site selection

    to ensure their trials run smoothly and on time? Let’s explore some key strategies that can help streamline the regulatory process and position organizations at the forefront of clinical advancements in Colombia.

    Understand the Regulatory Landscape for FIH Trials in Colombia

    Navigating the regulatory landscape for FIH clinical trial Colombia can be a daunting task for sponsors, yet it holds the key to unlocking efficient research pathways. Colombia’s regulatory framework is primarily overseen by the National Food and Drug Surveillance Institute (INVIMA). Understanding INVIMA’s regulations is not just beneficial; it’s essential for sponsors aiming to navigate the FIH clinical trial Colombia successfully. The validation process typically spans 60 to 90 days, which is notably faster than many other regions. Key requirements for successful submissions include:

    • Submission of a Clinical Trial Protocol: This document must detail the study design, objectives, and methodology, providing a comprehensive overview of the trial.
    • Ethics Committee Approval: Prior to submission to INVIMA, studies must secure approval from a registered Institutional Review Board (IRB) or Ethics Committee, ensuring ethical standards are met.
    • Compliance with ICH-GCP: All studies must adhere to the International Council for Harmonisation – Good Clinical Practice (ICH-GCP) standards, which are essential for maintaining the integrity and quality of clinical data.

    Mastering these regulations empowers organizations to streamline submissions and overcome common hurdles that often delay study initiation. Recent legislative changes, including Colombia’s Proyecto de Ley 191, aim to further enhance the efficiency of the approval process for FIH clinical trial Colombia, potentially reducing timelines and improving the overall landscape for these studies. Embracing these regulatory insights not only accelerates study initiation but also positions organizations at the forefront of clinical innovation in Colombia.

    This flowchart outlines the steps sponsors need to take to navigate the regulatory landscape for FIH clinical trials in Colombia. Each box represents a key action, and the arrows show the order in which these actions should be completed. Follow the flow to understand how to successfully initiate a clinical trial.

    Leverage Early Feasibility Studies to Enhance Trial Success

    Early feasibility studies (EFS) play a crucial role in the development of medical devices and pharmaceuticals, providing essential safety and efficacy data before advancing to larger trials. EFS in Colombia provides key advantages:

    • Regulatory Insights: EFS can uncover potential regulatory challenges early, allowing sponsors to make necessary adjustments prior to full-scale trials. bioaccess® assists in navigating the registration pathways with INVIMA, ANVISA, and COFEPRIS, ensuring compliance with local regulations and facilitating a streamlined approval process.
    • Cost Efficiency: By validating concepts at an early stage, sponsors can mitigate the risk of expensive late-stage failures, leading to significant resource savings. With bioaccess®, companies can achieve savings of approximately $25K per patient, significantly lowering overall study costs. The typical authorization timeline for clinical studies in Colombia is roughly 60 to 90 days, which is significantly quicker than in numerous other areas.
    • Patient Engagement: EFS typically involve smaller patient cohorts, allowing for closer interaction with participants and the collection of qualitative feedback that can inform further development. This method boosts data quality and speeds up patient recruitment, with bioaccess® facilitating faster enrollment processes.

    To fully leverage the benefits of EFS, sponsors should design studies that are robust and compliant with regulatory expectations, ensuring clear endpoints and methodologies that meet INVIMA’s standards. By leveraging bioaccess®’s expertise, sponsors can significantly enhance their chances of successful study outcomes and regulatory compliance.

    This mindmap illustrates the key benefits of early feasibility studies. Start at the center with EFS, then explore each branch to see how regulatory insights, cost efficiency, and patient engagement contribute to successful trials.

    Implement Effective Patient Recruitment Strategies for Timely Trials

    Patient recruitment is often the bottleneck in first-in-human (FIH) studies, leading to costly delays that can jeopardize research success. In Colombia, sponsors can adopt several effective strategies to enhance recruitment efforts:

    • Utilize Local Networks: Collaborating with local healthcare providers and community organizations is essential for identifying potential participants who meet eligibility criteria. Engaging with these networks can facilitate trust and improve participant willingness to enroll.
    • Culturally Tailored Communication: Developing recruitment materials in Spanish and considering cultural sensitivities can significantly enhance engagement. Clear, transparent communication about study objectives and participant expectations fosters trust and encourages participation.
    • Leverage Digital Platforms: Utilizing social media and online patient registries broadens outreach and attracts a diverse patient population. Digital tools can enhance the recruitment process, facilitating connections with potential participants and keeping them informed about study opportunities.

    By implementing these strategies, sponsors can transform recruitment efforts, paving the way for timely and successful FIH clinical trials in Colombia that meet both participant needs and regulatory standards. This proactive approach not only enhances participant engagement but also aligns with regulatory requirements set forth by INVIMA, ensuring compliance with ICH-GCP standards and facilitating a smoother pathway to regulatory approval.

    This mindmap shows the main strategies for recruiting patients in clinical trials. Each branch represents a different strategy, and the sub-branches provide specific actions to take. Follow the branches to see how each strategy contributes to successful recruitment.

    Optimize Site Selection and Activation for Efficient Trial Execution

    In the competitive landscape of clinical research, the choice and timely activation of investigation sites are pivotal for the success of the FIH clinical trial Colombia. Sponsors should adopt the following best practices:

    • Evaluate Site Experience: Prioritize sites with a strong history of conducting FIH trials and a thorough understanding of INVIMA regulations. This ensures compliance and enhances operational efficiency, critical for meeting regulatory standards.
    • Assess Patient Demographics: Choose sites strategically located in regions with a high prevalence of the target patient population. This method enhances recruitment and speeds up patient enrollment, which is crucial for maintaining study timelines.
    • Streamline Activation Processes: Initiate site activation as early as possible in the planning phase. Ensure that all essential documentation, including compliance clearances and site agreements, are in place to prevent delays. Taking this proactive approach can really cut down the time it takes to go from site selection to getting patients enrolled.

    By optimizing site selection and activation processes, sponsors not only enhance efficiency but also significantly improve their chances of achieving successful study results. Ultimately, a strategic approach to site selection and activation can be the difference between success and failure in clinical trials.

    This flowchart outlines the key steps to optimize site selection and activation in clinical trials. Follow the arrows to see how each practice connects and contributes to the overall efficiency of the trial process.

    Integrate U.S. Regulatory Standards with Latin American Execution for Faster Approvals

    Navigating the complexities of compliance in Colombia can be daunting, but aligning U.S. standards with local strategies can streamline the approval process for first-in-human studies. Here are key strategies sponsors can adopt:

    • Align Study Designs with FDA Expectations: Ensure that clinical trial designs adhere to FDA requirements, as this alignment can facilitate smoother submissions and acceptance of data from Colombian trials. This encompasses following ICH-GCP standards, which are essential for compliance with regulations.
    • Utilize Local Expertise: Engage with local CROs like bioaccess®, which specialize in navigating both U.S. and Colombian compliance landscapes. Their expertise ensures compliance with INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) regulations, enhancing operational efficiency and reducing the risk of delays.
    • Utilize Fast-Track Pathways: Capitalize on Colombia’s accelerated pathways, which can shorten timelines by up to 40% compared to conventional routes. By employing these pathways, organizations can attain regulatory clearance in as little as 30 days, significantly speeding up the clinical development process. bioaccess®’s Innovation Runway is designed to further accelerate clinical development for MedTech, Biopharma, and Radiopharma startups, helping them reach clinical milestones faster.

    By leveraging local expertise, sponsors can navigate these complexities more effectively, ensuring a smoother approval process. Embracing these strategies not only accelerates approvals but also positions sponsors for success in the competitive Colombian market.

    This flowchart outlines the key strategies for speeding up clinical trial approvals in Colombia. Each branch represents a strategy that can help sponsors navigate regulatory complexities and achieve quicker results.

    Conclusion

    Navigating the regulatory landscape for first-in-human (FIH) clinical trials in Colombia presents significant challenges that sponsors must overcome. This article has shared key strategies that can help sponsors streamline the approval process and improve trial outcomes. Organizations can significantly improve their chances of success by:

    1. Mastering INVIMA regulations
    2. Leveraging early feasibility studies
    3. Implementing effective patient recruitment strategies
    4. Optimizing site selection
    5. Integrating U.S. regulatory standards

    Key arguments presented emphasize the importance of early regulatory insights, cost efficiency, and patient engagement, all of which contribute to the overall effectiveness of clinical trials. The value of collaborating with local expertise and utilizing innovative pathways to expedite approvals cannot be overstated, as these factors lead to a more efficient trial process. By adopting these best practices, sponsors can navigate the complexities of FIH trials in Colombia and position themselves for clinical success.

    The message is straightforward: a strategic approach to FIH clinical trials in Colombia can speed up timelines, cut costs, and improve research quality. As the landscape of clinical development continues to evolve, sponsors are encouraged to leverage these insights and best practices to drive innovation and enhance patient care in the region. By doing so, they will not only contribute to the advancement of medical science but also establish a strong foothold in the dynamic Latin American market.

    Frequently Asked Questions

    What is the primary regulatory authority overseeing FIH clinical trials in Colombia?

    The primary regulatory authority overseeing FIH clinical trials in Colombia is the National Food and Drug Surveillance Institute (INVIMA).

    What is the typical validation process timeline for FIH clinical trials in Colombia?

    The typical validation process for FIH clinical trials in Colombia spans 60 to 90 days, which is faster than many other regions.

    What are the key requirements for submitting a clinical trial protocol to INVIMA?

    Key requirements for submitting a clinical trial protocol to INVIMA include the submission of a detailed Clinical Trial Protocol, obtaining Ethics Committee Approval from a registered Institutional Review Board (IRB) or Ethics Committee, and compliance with International Council for Harmonisation – Good Clinical Practice (ICH-GCP) standards.

    How can recent legislative changes, such as Proyecto de Ley 191, impact FIH clinical trials in Colombia?

    Recent legislative changes, including Proyecto de Ley 191, aim to enhance the efficiency of the approval process for FIH clinical trials in Colombia, potentially reducing timelines and improving the overall landscape for these studies.

    What advantages do early feasibility studies (EFS) provide in the context of clinical trials in Colombia?

    Early feasibility studies (EFS) provide several advantages, including uncovering potential regulatory challenges early, cost efficiency by validating concepts at an early stage, and enhanced patient engagement through smaller cohorts that allow for closer interaction and qualitative feedback.

    How does bioaccess® assist sponsors in navigating the regulatory pathways for clinical trials?

    bioaccess® assists sponsors by navigating the registration pathways with INVIMA, ANVISA, and COFEPRIS, ensuring compliance with local regulations and facilitating a streamlined approval process.

    What is the typical authorization timeline for clinical studies in Colombia?

    The typical authorization timeline for clinical studies in Colombia is approximately 60 to 90 days, which is significantly quicker than in many other areas.

    How can sponsors enhance their chances of successful study outcomes in Colombia?

    Sponsors can enhance their chances of successful study outcomes by designing robust studies that comply with regulatory expectations, ensuring clear endpoints and methodologies that meet INVIMA’s standards, and leveraging bioaccess®’s expertise.

    List of Sources

    1. Understand the Regulatory Landscape for FIH Trials in Colombia
      • linkedin.com (https://linkedin.com/pulse/colombia-rewriting-its-clinical-trial-rules-rest-martinez-clark-w7hme)
      • Latin America the ‘Hidden Gem’ for First-in-Human Medical Device Trials (https://clinicalresearchnewsonline.com/news/2025/08/14/latin-america-the-hidden-gem-for-first-in-human-medical-device-trials)
    2. Leverage Early Feasibility Studies to Enhance Trial Success
      • Early Feasibility Studies in Latin America (https://greenlight.guru/blog/early-feasibility-studies-in-latin-america)
      • meddeviceonline.com (https://meddeviceonline.com/doc/colombia-a-strategic-choice-for-medtech-clinical-trials-0001)
      • Quotes About Medical Research (https://changingthepresent.org/pages/quotes-about-medical-research)
    3. Implement Effective Patient Recruitment Strategies for Timely Trials
      • Latin America: A Compelling Region To Conduct Your Clinical Trials (https://clinicalleader.com/doc/latin-america-a-compelling-region-to-conduct-your-clinical-trials-0001)
      • Clinical studies: the challenge of patient recruitment (https://servier.com/en/newsroom/clinical-studies-patient-recruitment)
      • Enrollment in Clinical Trials: Statistics and Patient Recruitment Strategies | Power (https://withpower.com/guides/enrollment-in-clinical-trials-statistics-and-patient-recruitment-strategies)
      • What clinical trial statistics tell us about the state of research today (https://antidote.me/blog/what-clinical-trial-statistics-tell-us-about-the-state-of-research-today)
      • Seven Best Practices For Clinical Trial Patient Recruitment (https://openclinica.com/blog/seven-patient-recruitment-best-practices-used-by-leading-research-studies)
    4. Optimize Site Selection and Activation for Efficient Trial Execution
      • biobostonconsulting.com (https://biobostonconsulting.com/top-5-alarming-statistics-you-must-know-about-clinical-trial-site-selection)
      • Optimizing Site Selection and Management for Clinical Trial Success (https://studypages.com/blog/optimizing-site-selection-and-management-for-clinical-trial-success)
      • cryosite.com (https://cryosite.com/conducting-site-selection-the-key-factors-and-strategies-in-site-selection-for-clinical-trials)
      • Clinical Trial Site Selection: Key Factors & Best Practices | IntuitionLabs (https://intuitionlabs.ai/articles/clinical-trial-site-selection)
      • Strategies for Successful Site Selection in Clinical Trials (https://advarra.com/blog/strategies-for-successful-site-selection-in-clinical-trials)
    5. Integrate U.S. Regulatory Standards with Latin American Execution for Faster Approvals
      • Clinical trial timelines in flux: Considerations for U.S. and UK biopharma companies (https://rsmus.com/insights/industries/life-sciences/clinical-trial-timelines-in-flux.html)
      • ccrps.org (https://ccrps.org/clinical-research-blog/the-impact-of-regulatory-changes-on-clinical-trials-2025-analysis)
      • truveta.com (https://truveta.com/blog/news/fda-real-world-evidence-transparency)

  • Conducting a First-in-Human Clinical Trial in Colombia: A Step-by-Step Guide

    Conducting a First-in-Human Clinical Trial in Colombia: A Step-by-Step Guide

    Introduction

    In Colombia, the path to successful first-in-human (FIH) clinical trials is fraught with regulatory challenges that demand careful navigation. This guide aims to equip researchers and organizations with the insights needed to navigate these trials effectively, detailing essential steps from regulatory compliance to patient recruitment strategies. Navigating these complexities can lead to significant setbacks if not managed properly. To overcome these challenges, trial sponsors must adopt strategic approaches that leverage local insights.

    Understand the Regulatory Landscape for FIH Trials in Colombia

    To navigate the complexities of conducting a first-in-human clinical trial in Colombia, a thorough understanding of the regulatory framework is crucial. The Instituto Nacional de Vigilancia de Medicamentos y Alimentos oversees this framework, and here are the key steps to follow:

    1. Get Acquainted with Regulatory Guidelines: Review the latest guidelines from the regulatory authority, particularly Resolution 2378/2008, which outlines the requirements for research studies. This includes understanding the types of studies that require approval and the specific documentation needed.
    2. Approval Timelines: The regulatory authority typically assesses clinical study applications within 60 to 90 days. Delays can occur if submissions are incomplete or trials are complex. Significantly, the fast-track rare disease pathway has allowed companies such as Unravel Biosciences to initiate patient dosing in less than 90 days, showcasing the effectiveness of expedited processes in the region.
    3. Documentation Requirements: Prepare essential documents such as the Clinical Trial Protocol, Informed Consent Forms, Investigator’s Brochure, and any preclinical data that supports the safety and efficacy of the investigational product.
    4. Ethics Committee Approval: Before submitting to INVIMA, obtain approval from a local ethics committee. Expect this process to take about 30 to 45 days, depending on how the committee is scheduled.
    5. Adherence to ICH-GCP: Ensure that your study complies with International Council for Harmonisation – Good Clinical Practice (ICH-GCP) standards, as this is a requirement for acceptance by authorities and enhances the credibility of your data.

    Have you considered how submission completeness and trial complexity might affect your approval timeline? By comprehending these compliance aspects, you can optimize the approval process and reduce potential delays in the first-in-human clinical trial in Colombia. By leveraging Colombia’s regulatory framework, you can not only streamline your approval process but also enhance the likelihood of your study’s success in a competitive landscape.

    This flowchart outlines the steps you need to follow for conducting a first-in-human clinical trial in Colombia. Each box represents a key step, and the arrows show the order in which you should complete them. Following this path will help you navigate the regulatory landscape effectively.

    Prepare Essential Preclinical Data and Documentation

    Meticulous preparation of preclinical data is non-negotiable before embarking on a first-in-human clinical trial in Colombia. Follow these essential steps to ensure a successful process:

    1. Conduct Preclinical Studies: Complete necessary preclinical studies, including pharmacology, toxicology, and pharmacokinetics. These studies must demonstrate the safety and biological activity of the investigational product, providing a solid foundation for human evaluations.

    2. Compile a Preclinical Dossier: Create a detailed dossier that includes:

      • A summary of preclinical studies
      • Results from animal studies, including dosing and toxicity data
      • Justification for the proposed starting dose in humans
      • Relevant manufacturing information that supports product quality.

    3. Prepare the Clinical Study Protocol: Draft a clear and concise clinical study protocol outlining the study design, objectives, methodology, and statistical analysis plan. This document is crucial for regulatory submission to the relevant authorities and operational execution.

    4. Informed Consent Forms: Develop informed consent forms that clearly explain the trial’s purpose, procedures, risks, and benefits to potential participants. These forms must receive approval from the ethics committee before submission to INVIMA.

    5. Investigator’s Brochure: Create an Investigator’s Brochure that offers detailed information about the investigational product, including its pharmacological properties, safety profile, and any prior trial data.

    Thorough preparation of these documents not only boosts your approval odds but also paves the way for a seamless transition into the research phase. In Colombia, where regulatory pathways are efficient, prompt submission and compliance with ICH-GCP standards can greatly expedite the study process, positioning it as a prime location for the first-in-human clinical trial in Colombia.

    Each box represents a crucial step in preparing for a clinical trial. Follow the arrows to see how each step leads to the next, ensuring all necessary documentation is completed before moving forward.

    Execute the Trial: Site Selection, Recruitment, and Monitoring

    Conducting a first-in-human clinical trial in Colombia presents unique challenges that demand meticulous planning and oversight. Here’s how to effectively execute your trial:

    1. Site Selection: Choose clinical study sites that are experienced and equipped to conduct FIH studies. Consider factors such as:

      • Proximity to patient populations, which enhances recruitment potential.
      • Availability of trained staff familiar with FIH protocols.
      • Prior experience with similar studies, ensuring a smoother execution.
      • Compliance with ICH-GCP and INVIMA regulations, as well as the COFEPRIS 30-day approval pathway for medical devices, to meet local standards.

    2. Patient Recruitment: Develop a robust patient recruitment strategy that includes:

      • Engaging with local healthcare providers to identify potential participants, leveraging their networks for referrals.
      • Utilizing digital marketing and social media to reach a broader audience, as nearly 50% of potential participants learn about clinical studies through these channels.
      • Providing clear details about the study’s advantages and risks to promote participation, which can reduce financial anxiety and improve engagement.
      • Consider implementing virtual pre-screening visits. This approach removes barriers to enrollment and allows potential participants to assess their eligibility without the need to travel.

    3. Monitoring and Data Collection: Implement a comprehensive monitoring plan to ensure compliance with the protocol and regulatory requirements. This includes:

      • Regular site visits to assess adherence to the protocol and ICH-GCP standards, which can help mitigate dropout rates that affect trial integrity.
      • Training site staff on data collection procedures and reporting requirements to ensure accuracy and reliability.
      • Utilizing electronic data capture systems to streamline data collection and enhance accuracy, facilitating real-time monitoring of study progress.

    4. Safety Monitoring: Establish a safety monitoring plan that includes:

      • Regular review of adverse events and serious adverse events to ensure participant safety.
      • Communication with the ethics committee and INVIMA regarding any safety concerns, maintaining transparency and adherence to compliance expectations.

    By efficiently overseeing these operational elements, you enhance the quality of your study and ensure compliance with standards. This approach leads to successful outcomes in the fast-paced realm of first-in-human clinical trial in Colombia. Furthermore, utilizing bioaccess®’s Innovation Runway can expedite your development process, aiding you in achieving essential milestones more swiftly and securing funding before your runway expires.

    This flowchart illustrates the steps involved in executing a clinical trial. Each box represents a key area of focus, and the arrows show how these areas connect and flow into one another. Follow the arrows to understand the sequence of actions needed for a successful trial.

    Analyze Data and Submit Regulatory Findings

    Navigating the regulatory landscape after a first-in-human clinical trial in Colombia is crucial for ensuring the success of your investigational product. Here’s a structured approach to ensure compliance and enhance the credibility of your submission:

    1. Data Analysis: Conduct a comprehensive analysis of the collected data, emphasizing:

      • Safety and efficacy outcomes, ensuring all adverse events are documented.
      • Statistical significance of the results, utilizing appropriate statistical methods to validate findings.
      • Any unexpected findings that may influence the overall assessment of the investigational product, which should be clearly articulated in the report.

    2. Prepare the Clinical Study Report (CSR): Draft a detailed CSR that adheres to INVIMA’s requirements, including:

      • Study Objectives and Design: Clearly outline the purpose of the trial and the methodology employed.
      • Methodology and Statistical Analysis: Describe the study design, including participant selection, intervention details, and statistical methods used for analysis.
      • Results and Discussion: Present the findings in a clear format, supported by tables and figures, and discuss their implications in the context of existing literature.
      • Conclusions and Recommendations: Summarize the key findings and suggest directions for future research, including potential modifications for subsequent trials.

    3. Regulatory Submission: Submit the CSR along with any additional required documents to INVIMA, ensuring:

      • All documents are formatted according to INVIMA guidelines, which include specific sections mandated by the ICH-GCP standards.
      • Inclusion of supplementary data that supports your findings, such as safety reports and patient feedback, which can enhance the robustness of your submission.

    4. Follow-Up with INVIMA: After submission, maintain open communication with INVIMA to address any inquiries or requests for further information. Staying engaged with INVIMA not only helps address any questions but also shows your dedication to meeting regulatory standards.

    5. Prepare for Future Studies: Leverage insights gained from the study to inform the design of subsequent research, whether they involve larger patient populations or different investigational products. This iterative method not only enhances study design but also increases the chances of approval success.

    By meticulously analyzing your data and effectively communicating your findings through a well-structured CSR, you can significantly bolster the credibility of your trial and support future regulatory submissions, ultimately accelerating the path to market for your investigational product.

    This flowchart guides you through the steps needed after a clinical trial. Each box represents a key stage in the process, and the arrows show the order in which you should complete them. Follow the steps to ensure your submission is thorough and compliant!

    Conclusion

    Conducting a first-in-human clinical trial in Colombia presents unique challenges and opportunities that demand a strategic approach. Understanding the essential steps – like navigating INVIMA guidelines and ensuring compliance with ICH-GCP standards – allows researchers to optimize their trial processes and boost their chances of success. Colombia’s efficient regulatory pathways and supportive environment for clinical research make it a strategic choice for early-stage trials, particularly in the MedTech and biopharma sectors. However, navigating these pathways requires careful planning and adherence to regulations.

    Key arguments highlighted in this guide include the importance of thorough documentation preparation, such as preclinical data and informed consent forms, as well as the necessity of selecting appropriate trial sites and developing effective patient recruitment strategies. Every step, from choosing the right sites to analyzing data, is vital for meeting regulatory requirements and ensuring participant safety and data integrity. Engaging with local ethics committees and maintaining open communication with INVIMA further solidifies the credibility of the research.

    As the landscape for clinical trials continues to evolve, this evolving landscape offers both opportunities and challenges for researchers looking to bring innovative products to market. Stakeholders are encouraged to adopt best practices outlined in this guide, ensuring that they remain compliant while fostering innovation. By strategically navigating these complexities, organizations can not only enhance their trial outcomes but also play a pivotal role in advancing medical innovation in Colombia.

    Frequently Asked Questions

    What is the role of the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) in FIH trials in Colombia?

    INVIMA oversees the regulatory framework for conducting first-in-human (FIH) clinical trials in Colombia, ensuring compliance with established guidelines and requirements.

    What are the key regulatory guidelines to review for conducting FIH trials in Colombia?

    It is essential to review the latest guidelines from INVIMA, particularly Resolution 2378/2008, which outlines the requirements for research studies, including the types of studies that need approval and the specific documentation required.

    What is the typical approval timeline for clinical study applications in Colombia?

    The regulatory authority typically assesses clinical study applications within 60 to 90 days. However, delays may occur if submissions are incomplete or if the trials are complex.

    What documentation is required for submitting an FIH trial in Colombia?

    Essential documents include the Clinical Trial Protocol, Informed Consent Forms, Investigator’s Brochure, and any preclinical data supporting the safety and efficacy of the investigational product.

    Is ethics committee approval necessary before submitting to INVIMA?

    Yes, approval from a local ethics committee is required prior to submission to INVIMA. This process usually takes about 30 to 45 days, depending on the committee’s scheduling.

    What standards must be adhered to for FIH trials in Colombia?

    Studies must comply with International Council for Harmonisation – Good Clinical Practice (ICH-GCP) standards, as this is a requirement for acceptance by authorities and enhances the credibility of the data.

    How can submission completeness and trial complexity affect the approval timeline?

    Incomplete submissions or complex trials can lead to delays in the approval process. Understanding these compliance aspects can help optimize the approval timeline and reduce potential delays.

    What advantages does Colombia offer for early-stage clinical trials?

    Colombia offers advantages such as expedited approval processes, cost efficiency, and access to a diverse patient population, making it a strategic location for early-stage clinical trials in Latin America.

    List of Sources

    1. Understand the Regulatory Landscape for FIH Trials in Colombia
      • linkedin.com (https://linkedin.com/pulse/colombia-rewriting-its-clinical-trial-rules-rest-martinez-clark-w7hme)
      • alzforum.org (https://alzforum.org/news/conference-coverage/nih-director-announces-100m-prevention-trial-genentech-antibody)
    2. Prepare Essential Preclinical Data and Documentation
      • Beyond the Safety Check: Why First-in-Human Trials Demand a New Approach in 2026 | BioPharm International (https://biopharminternational.com/view/safety-first-human-trials-new-approach)
      • First-in-Human Trial Participants: Not a Vulnerable Population, but Vulnerable Nonetheless – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC2692671)
      • finance.yahoo.com (https://finance.yahoo.com/news/wave-life-sciences-announced-positive-201500678.html)
    3. Execute the Trial: Site Selection, Recruitment, and Monitoring
      • Patient Recruitment for Clinical Trials: Strategies That Actually Work (https://kapsuletech.com/blog/patient-recruitment-clinical-trials)
      • veristat.com (https://veristat.com/patient-recruitment-for-clinical-trials)
      • globenewswire.com (https://globenewswire.com/news-release/2026/01/22/3223958/0/en/clinical-trial-patient-recruitment-services-market-report-2026-2032-how-digital-and-physician-engagements-are-transforming-participant-enrollment.html)
      • gcihealth.com (https://gcihealth.com/2026/01/22/precision-relevance-and-prediction-the-future-of-clinical-trial-recruitment)
      • Strategies for Successful Site Selection in Clinical Trials (https://advarra.com/blog/strategies-for-successful-site-selection-in-clinical-trials)
    4. Analyze Data and Submit Regulatory Findings
      • linkedin.com (https://linkedin.com/pulse/clinical-study-reports-drug-development-comprehensive-hiep-ben–gensc)
      • Clinical Study Reports : Types and Use Cases (https://precisionformedicine.com/blog/clinical-study-reports-csr-types-and-use-cases)
      • easyglobaltraining.com (https://easyglobaltraining.com/blogs/what-fda-reviewers-really-look-for-in-a-clinical-study-report?srsltid=AfmBOoqW3j3I4W2ieOgE8cBS8usmL0z1vM6CeCNfbtY5HrqrQjaloqN1)
      • biopharmaservices.com (https://biopharmaservices.com/blog/bioequivalence-clinical-study-report-development-of-generic-products)

  • Ophthalmic First-In-Human Studies In Latin America: Why Smaller Markets Often Move Fastest

    Ophthalmic First-in-Human Studies in Latin America: Why Smaller Markets Often Move Fastest

    For ophthalmic medical device founders running their first-in-human (FIH) program — intravitreal injectors, glaucoma microshunts, retinal delivery platforms, intraocular lens innovations — the conventional wisdom says you go to a country with the largest patient pool and the most prestigious eye institutes. In Latin America, that usually points sponsors toward Mexico or Brazil first.

    That instinct is right for pivotal studies. For an FIH or early-feasibility study with 5 to 15 patients, however, our operational experience consistently shows a different pattern: smaller markets like El Salvador, Panama, and the Dominican Republic often deliver a faster path to first patient in. Here is why, and how to think about country selection for an ophthalmic FIH program.

    The FIH Math Is Different from the Pivotal Math

    Pivotal studies select for patient pool depth, statistical power, and reimbursement signal. FIH studies select for something else entirely: speed to first dose, regulatory predictability, and quality of investigator engagement on a small handful of patients.

    For a 10-patient ophthalmic FIH study, the binding constraint is rarely “are there enough eligible patients in the country” — almost any LATAM country has thousands of glaucoma, AMD, or refractive candidates. The binding constraints are:

    • Time from sponsor decision to first ethics committee submission
    • Time from EC approval to first patient screened
    • Investigator focus and availability across the dosing window
    • Regulatory predictability for a novel device class

    On all four, smaller markets often outperform the regional giants for FIH-stage work.

    Why Smaller Markets Move Faster on Ophthalmic FIH

    Three structural factors explain it.

    1. Lighter EC and regulatory queues. An ethics committee at a leading eye hospital in El Salvador or Panama might review three to six device protocols per quarter. The equivalent committee at a top São Paulo or Mexico City institute might be working through 30 to 60. Both are competent and rigorous; one simply has more capacity for a fast-track FIH protocol.

    2. Concentrated investigator attention. In smaller markets, a leading ophthalmologist running an FIH study is not splitting attention across 12 simultaneous trials. The principal investigator has direct line of sight on every screening visit, every dosing event, every follow-up — the kind of operational intimacy that materially reduces protocol deviations and data queries on a small-N study.

    3. Tighter sponsor-to-site communication. Smaller hospital systems mean fewer layers between sponsor, CRO, principal investigator, and ethics coordinator. A protocol clarification that takes a week to circulate at a large academic center can be resolved in a 30-minute call in a smaller setting.

    What This Looks Like in Practice for an Ophthalmic FIH

    For an intravitreal device, glaucoma microshunt, or refractive implant FIH program, a well-structured small-market approach typically looks like this:

    • Single-country FIH (5–10 patients). Concentrate enrollment at one or two specialized eye centers in a smaller market. Optimize for speed and data quality, not geographic diversity.
    • Validated translation and regulatory packets ready before EC submission. Smaller markets are fast on substance but unforgiving on document inconsistency.
    • Compressed feasibility-to-FPI window. A 6 to 8 week target from sponsor go-decision to first patient enrolled is achievable when site, EC, and country regulator are aligned from day one.
    • Clean handoff to a multi-country pivotal. Once FIH safety data is in hand, the pivotal can move to Mexico, Brazil, Argentina, or a multi-country footprint with the FIH evidence already supporting site selection conversations.

    When the Conventional Path Still Wins

    Smaller markets are not the right choice for every ophthalmic FIH. Three situations argue for going to Mexico or Brazil first:

    • Genetic ophthalmic indications where a specific sub-population is concentrated in one large country.
    • Complex imaging endpoints requiring a specific OCT, ultra-widefield imaging, or AI-assisted analysis platform that is only operational at a handful of large academic centers in the region.
    • Founder-led key opinion leader strategy where the FIH publication-to-investor narrative depends on a specific principal investigator’s involvement.

    For most early-stage ophthalmic device sponsors, however, the speed advantage of smaller markets at the FIH stage translates directly into reduced cash burn during the most capital-fragile window of the company’s life. In an industry where 90% of MedTech startups fail because they run out of capital before generating clinical evidence, that compression matters.

    Frequently Asked Questions

    How quickly can a well-designed ophthalmic FIH actually start in a smaller LATAM market?
    With prepared documents, an experienced site, and a clear regulatory pathway, 6 to 10 weeks from contract signature to first patient screened is realistic. The variability comes from how prepared the sponsor’s regulatory packet is, not from the country’s regulatory speed.

    Will FDA accept FIH data from El Salvador, Panama, or the Dominican Republic?
    Yes, under 21 CFR 812.28, provided the study is conducted in compliance with ICH-GCP. The FDA does not maintain a country whitelist; it evaluates each study on the quality of its execution, documentation, and ethics oversight.

    Should we run the FIH in a smaller market and then move the pivotal to Brazil or Mexico?
    This is a common and effective sequencing strategy for ophthalmic device programs. Smaller markets optimize for speed at the FIH stage. Larger markets optimize for enrollment depth, infrastructure, and regulatory signal at the pivotal stage. Designing the FIH protocol with the eventual pivotal in mind — same imaging modalities, same primary endpoint definitions, same data capture standards — makes the transition seamless.

    bioaccess® is the world’s only contract research organization built exclusively for first-in-human medical device trials, operating across 10 Latin American countries. Explore the FIH playbook at bioaccessla.com or estimate a study at bioaccessla.com/clinical-trial-calculator.

  • 4 Reasons CROs Choose Brazil for First-in-Human Trials

    4 Reasons CROs Choose Brazil for First-in-Human Trials

    Introduction

    As Brazil positions itself as a pivotal player in first-in-human trials, the stakes for clinical research organizations have never been higher. This country leverages its diverse demographics and advanced healthcare infrastructure to provide a rich pool of treatment-naive patients, essential for generating high-quality clinical data. Additionally, Brazil boasts significant cost efficiencies and expedited regulatory processes that can reduce timelines by up to 65%. However, navigating the evolving landscape of regulations and competitive pressures poses significant challenges for clinical research organizations in Brazil. To thrive in this dynamic environment, organizations must develop strategic approaches that leverage Brazil’s unique advantages.

    Explore Brazil’s Strategic Advantages for First-in-Human Trials

    This nation stands out as a premier destination for CRO Brazil first-in-human clinical studies, driven by its unique demographic and healthcare advantages. The country’s demographic diversity facilitates the recruitment of treatment-naive individuals, a vital component for ensuring the integrity of FIH studies. With over 210 million residents, the urban areas of this nation offer access to a diverse array of profiles, improving the generalizability of research outcomes.

    Furthermore, the healthcare system in the country is well-equipped with state-of-the-art medical facilities and a network of seasoned research organizations like Bioaccess, which specializes in CRO Brazil first-in-human studies. Bioaccess® leverages its strong regulatory ties with ANVISA and INVIMA to drive efficient patient recruitment and retention, essential elements for the success of early-stage studies. Recent regulatory reforms, such as Law 14.874/2024, have streamlined the approval process. Now, Bioaccess® can secure ethics approvals on a timeline set by each committee’s meeting schedule, a stark contrast to the typical 6-12 months in the US. This efficiency, along with the cost reductions of up to 30% compared to US studies, makes this nation an increasingly appealing choice for sponsors seeking to accelerate their clinical development timelines.

    With these advancements, sponsors can not only expedite their timelines but also enhance the quality of their clinical research outcomes.

    This mindmap shows the key reasons why Brazil is a great choice for first-in-human trials. Each branch represents a different advantage, and the sub-branches provide more details. Follow the branches to understand how these factors work together to make Brazil an appealing option for clinical research.

    Leverage Cost Efficiency and Speed in Brazilian CROs

    Conducting first-in-human studies in Brazil presents a compelling alternative to the high costs and lengthy timelines of conventional markets like the U.S. Clinical studies in this country generally cost 25-35% less than comparable research in these areas, primarily due to reduced site fees and operational costs. The bioaccess® sample budget puts a first-in-human study in Latin America at about $430K for 20 subjects with a minimally invasive device and about $1.32M for 10 subjects with a surgical implant (illustrative, not a quote; see bioaccessla.com/sample-budget-fih-trial-latin-america).

    Moreover, Brazil has significantly reduced approval timelines, making it more attractive for clinical studies. Recent legislative modifications, including Law #14.874/2024, have cut the average approval duration for studies from 265 days to around 90 days. This faster timeline is vital for startups looking to generate data quickly, attract investors, and bring their products to market.

    How can sponsors leverage insights and market access strategies from bioaccess’s Global Trial Accelerators™ to optimize resources and navigate the regulatory landscape effectively? By doing so, they can ensure compliance with ANVISA regulations and ICH-GCP standards. This positions Brazil as an increasingly appealing location for CRO Brazil first-in-human studies, especially for MedTech, Biopharma, and Radiopharmaceutical firms aiming to expedite their development processes.

    With these advantages, Brazil is poised to become a key player in the global MedTech landscape, inviting innovators to seize the opportunity for growth and collaboration.

    This chart shows how much cheaper it is to conduct studies in Brazil compared to the U.S., as well as how much faster the approval process is. The green section represents the cost savings, while the blue section illustrates the reduction in approval days.

    The evolving regulatory landscape in Brazil presents both challenges and opportunities for clinical research sponsors. The regulatory framework for clinical studies in the country is supervised by ANVISA (Agência Nacional de Vigilância Sanitária), which has implemented significant reforms to improve the approval process. The introduction of Law 14.874/2024 aligns Brazil’s regulations with international Good Clinical Practice (GCP) standards, thus creating a more predictable and efficient pathway for CRO Brazil first-in-human studies.

    Under these new regulations, the average review time for ethical approval has been lowered from 45 days to around 30 days, allowing sponsors to commence studies more swiftly. Additionally, submitting research study applications alongside other regulatory filings boosts operational efficiency. Navigating the complexities of regulatory approval can often be daunting for sponsors, but this regulatory clarity safeguards patient safety and empowers them to plan their studies with increased confidence, knowing that the approval process is both transparent and expedited.

    The recent Executive Order #12,651/2025 commits to a 90-business-day turnaround for responses to new study submissions, further enhancing this landscape. This initiative seeks to greatly enhance the number of medical studies performed in Brazil, with forecasts indicating that the count of these studies could double in the upcoming years. By effectively navigating this evolving regulatory environment, CROs can ensure compliance with ICH-GCP standards while minimizing delays, ultimately leading to faster access to critical trial data. With bioaccess®’s Global Trial Accelerators™, sponsors can utilize these benefits to improve their market access strategies and achieve successful results in their studies. By leveraging these regulatory advancements, sponsors can not only expedite their studies but also enhance their competitive edge in the market.

    This flowchart illustrates the key reforms in Brazil's regulatory landscape for clinical research. Each step shows how changes in regulations lead to faster approvals and improved study planning for sponsors. Follow the arrows to see how each reform connects and contributes to a more efficient process.

    Access Treatment-Naive Patient Cohorts for Enhanced Outcomes

    Brazil’s unique position as a hub for clinical research is exemplified by its role in CRO Brazil first-in-human studies, stemming from its access to treatment-naive populations, which is a critical factor. These individuals, who have not previously received treatment for their conditions, are essential for evaluating the safety and efficacy of new therapies. Brazil’s diverse population, with its rich mix of ethnicities and health profiles, provides a vital pool of treatment-naive candidates essential for high-quality research data.

    Recruiting individuals who have not undergone treatment significantly enhances the credibility of study results and contributes to impressive retention rates. Brazilian clinical studies often achieve retention rates exceeding 95%, a figure that surpasses many other regions. This impressive retention stems from how CROs in Brazil engage with communities and educate patients, building trust and commitment. By leveraging these treatment-naive groups, sponsors of CRO Brazil first-in-human studies can ensure that their studies generate robust and reliable data, ultimately accelerating regulatory approvals and enabling faster market entry.

    Moreover, the Brazilian regulatory landscape, governed by authorities such as ANVISA, supports efficient approval processes, further enhancing the attractiveness of conducting trials in this region. This regulatory framework not only accelerates approvals but also elevates the quality of research in Brazil. The Innovation Runway by bioaccess® has utilized this environment, allowing MedTech, Biopharma, and Radiopharma startups to achieve milestones 40% faster. The Brazil clinical trials market was valued at USD 571.3 million in 2025 and is projected to reach USD 1,033.6 million by 2033, reflecting the growing demand for clinical research in this vibrant market. As the demand for clinical research grows, Brazil’s landscape offers unparalleled opportunities for innovation and collaboration.

    This mindmap illustrates the interconnected factors that make Brazil a hub for clinical research. Start at the center with the main theme, then explore each branch to understand how treatment-naive populations, high retention rates, supportive regulations, and market growth contribute to the success of clinical trials in Brazil.

    Conclusion

    Why is Brazil becoming the go-to destination for first-in-human (FIH) trials? Brazil has emerged as a leading choice, offering a unique blend of demographic diversity, cost efficiency, and an evolving regulatory environment that benefits sponsors in the MedTech and Biopharma sectors. Contract research organizations (CROs) can tap into Brazil’s rich patient population and streamlined processes. This allows them to conduct high-quality clinical studies more effectively than in traditional markets like the U.S. and EU.

    The advantages of conducting FIH trials in Brazil are compelling. Access to a treatment-naive patient population, significantly reduced costs – up to 30% lower than in the U.S. – and expedited approval timelines are just a few. Recent legislative reforms have allowed for ethics approvals on a timeline set by each committee’s meeting schedule. With Brazil’s strong healthcare infrastructure and the know-how of organizations like Bioaccess®, sponsors can easily navigate the regulatory landscape, enhancing the overall quality and reliability of clinical research outcomes.

    As demand for clinical trials rises, have you considered how Brazil could be your strategic hub for innovation and collaboration in early-stage research? By choosing Brazil for FIH studies, sponsors not only benefit from faster timelines and lower costs but also position themselves to capitalize on the rich opportunities this vibrant market offers. Ignoring Brazil’s potential could mean missing out on groundbreaking advancements in clinical research.

    Frequently Asked Questions

    Why is Brazil considered a premier destination for first-in-human (FIH) clinical trials?

    Brazil’s demographic diversity and well-equipped healthcare system make it an attractive location for FIH clinical trials. The country has over 210 million residents, allowing for the recruitment of treatment-naive individuals, which is essential for the integrity of FIH studies.

    What advantages does Brazil offer in terms of patient recruitment for clinical studies?

    The urban areas of Brazil provide access to a diverse array of profiles, improving the generalizability of research outcomes. This demographic diversity facilitates efficient recruitment of treatment-naive individuals, which is crucial for FIH trials.

    How does the healthcare system in Brazil support early-stage clinical trials?

    Brazil’s healthcare system is equipped with state-of-the-art medical facilities and a network of experienced research organizations like Bioaccess, which specializes in FIH studies. These organizations leverage strong regulatory ties with ANVISA and INVIMA to enhance patient recruitment and retention.

    What recent regulatory reforms have impacted the approval process for clinical trials in Brazil?

    Recent reforms, particularly Law 14.874/2024, have streamlined the approval process, allowing organizations like Bioaccess to secure ethics approvals on a timeline set by each committee’s meeting schedule, compared to the typical 6-12 months in the US.

    How does the cost of conducting clinical trials in Brazil compare to the US?

    Conducting clinical trials in Brazil can result in cost reductions of up to 30% compared to studies in the US, making it a more appealing choice for sponsors looking to accelerate their clinical development timelines.

    What benefits do sponsors gain by conducting FIH studies in Brazil?

    Sponsors can expedite their clinical development timelines, enhance the quality of research outcomes, and benefit from efficient patient recruitment and retention due to the country’s regulatory advantages and demographic diversity.

    List of Sources

    1. Explore Brazil’s Strategic Advantages for First-in-Human Trials
      • expertmarketresearch.com (https://expertmarketresearch.com/reports/brazil-clinical-trials-market)
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/brazil)
      • fortunebusinessinsights.com (https://fortunebusinessinsights.com/brazil-clinical-trials-market-112310)
    2. Leverage Cost Efficiency and Speed in Brazilian CROs
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/brazil)
      • lek.com (https://lek.com/insights/life-sciences-pharma/unlocking-brazils-clinical-trial-opportunity-strategic-roadmap)
      • fortunebusinessinsights.com (https://fortunebusinessinsights.com/brazil-clinical-trials-market-112310)
    3. Navigate the Regulatory Landscape for Swift Approvals
      • lickslegal.com (https://lickslegal.com/post/new-regulations-for-clinical-research-in-brazil)
      • ensaiosclinicos.gov.br (https://ensaiosclinicos.gov.br/news/566)
      • clinicalleader.com (https://clinicalleader.com/doc/how-brazil-s-new-law-is-redefining-the-country-s-clinical-research-0001)
    4. Access Treatment-Naive Patient Cohorts for Enhanced Outcomes
      • lek.com (https://lek.com/insights/life-sciences-pharma/unlocking-brazils-clinical-trial-opportunity-strategic-roadmap)
      • link.springer.com (https://link.springer.com/article/10.1186/s12879-025-11700-0)
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/brazil)
      • fortunebusinessinsights.com (https://fortunebusinessinsights.com/brazil-clinical-trials-market-112310)

  • 4 Best Practices for First in Human Biopharma Trials in Chile

    4 Best Practices for First in Human Biopharma Trials in Chile

    Introduction

    While Chile’s regulatory framework offers promising approval timelines for first-in-human biopharma trials, the path to success is fraught with challenges that sponsors must navigate. As a strategic hub for clinical research in Latin America, Chile presents significant opportunities. Yet, the complexities of compliance, patient recruitment, and site selection present significant hurdles that can hinder progress.

    What strategies can sponsors implement to not only leverage Chile’s advantages but also navigate these obstacles for successful trial outcomes?

    Understand Regulatory Frameworks for FIH Trials in Chile

    Understanding the regulatory landscape for first in human biopharma Chile is crucial for sponsors aiming to expedite their clinical research efforts. Conducting FIH studies requires a thorough understanding of the frameworks established by the Instituto de Salud Pública (ISP) and strict adherence to ICH-GCP standards. The approval process is efficient, typically taking around 30 business days, positioning Chile as an attractive destination for sponsors seeking expedited timelines.

    Key regulations include:

    However, many sponsors find the regulatory landscape daunting due to its complexity and the need for meticulous preparation. To navigate this landscape effectively, sponsors need to prepare a detailed Clinical Trial Application (CTA). This should include:

    • Thorough study protocols
    • Patient safety measures
    • Robust data management plans

    Acquaintance with these guidelines not only simplifies the approval process but also enhances the credibility of study data, which is crucial for subsequent submissions to authorities such as the FDA. As of 2024, Chile ranks fourth among Latin American nations for research studies, highlighting its growing importance. This shift in research activity underscores the need for sponsors to act swiftly and strategically to capitalize on Chile’s favorable conditions for successful first in human biopharma Chile studies.

    This flowchart guides you through the steps needed to navigate the regulatory landscape for FIH trials in Chile. Start with understanding the regulations, then prepare your application, and follow through to the approval process. Each box represents a key step, and the arrows show how they connect.

    Conduct Early Feasibility Studies to Validate Trial Designs

    Early feasibility studies (EFS) are not just a formality; they are essential for validating study designs and ensuring project success in clinical research. In Chile, EFS offers vital insights into patient safety and device functionality, contributing to the advances of first in human biopharma Chile. These insights are crucial for navigating the complex compliance landscape. Typically involving a small cohort of participants – often ten or fewer – EFS focus on gathering initial data that can inform larger trials.

    To really make EFS work, sponsors need to connect with local clinical experts who know the ins and outs of compliance, including adherence to ICH-GCP standards and the requirements set forth by local authorities like the Instituto de Salud Pública (ISP). Utilizing feedback from participants during these studies is also essential, as it aids in refining protocols and improving the overall quality of the data gathered.

    Additionally, leveraging Chile’s diverse population can greatly enhance the generalizability of findings, making the data more reliable for future submissions. The streamlined regulatory pathways in Latin America, along with the capacity to obtain regulatory approval on a study-specific timeline set by the protocol and each regulator’s review, position EFS as a strategic asset for early-stage trials, particularly as the first in human biopharma Chile. Moreover, sponsors can realize significant cost savings, estimated at $25K per individual, which can be reinvested into research and development or future funding milestones. By leveraging EFS effectively, sponsors can not only enhance their study designs but also secure a competitive edge in the clinical research landscape.

    This flowchart illustrates the steps involved in conducting Early Feasibility Studies. Each box represents a key action in the process, and the arrows show how these actions connect to achieve successful clinical trials.

    Implement Targeted Patient Recruitment Strategies

    Effective recruitment of participants is not just important; it’s essential for the success of first in human biopharma Chile studies. Sponsors should implement targeted strategies that resonate with the local population, including engaging community health organizations and local healthcare providers. Utilizing social media platforms for outreach can significantly enhance visibility and participation. Offering incentives for participation, such as financial compensation for time and travel, can further motivate potential participants. Additionally, ensuring that recruitment materials are culturally sensitive and accessible is crucial for maximizing enrollment rates.

    Patient registries and databases can help identify individuals who meet study criteria. This enhances the recruitment process. In Chile, where 37% of study centers fail to meet their recruitment targets, these strategies are vital for achieving enrollment goals. Without effective recruitment, studies may face delays or fail altogether. Furthermore, the integration of bilingual U.S. board-certified physicians in the recruitment process enhances communication and trust, which are critical for participant retention. By implementing these thorough recruitment strategies, sponsors can guarantee a diverse and representative sample, ultimately enhancing the credibility of study results.

    At bioaccess®, our founders-distinguished specialists like Dr. Martinez-Clark and Dr. O’Neill-bring their extensive expertise to expedite studies and tackle compliance hurdles in Latin America. Their dedication to closing the divide between medical innovation and research ensures that our clients can efficiently carry out studies in first in human biopharma Chile, benefiting from the strategic advantages of the region. Furthermore, adherence to local oversight bodies such as INVIMA is crucial to navigate the operational landscape effectively, ensuring that all recruitment strategies align with compliance requirements. By prioritizing these strategies, sponsors can not only enhance enrollment but also contribute to the future of medical research in Latin America.

    This mindmap starts with the main idea of patient recruitment strategies at the center. Each branch represents a key area of focus, and the sub-branches provide specific actions or considerations related to that area. Follow the branches to see how different strategies connect and contribute to successful recruitment.

    Select and Activate Clinical Trial Sites Efficiently

    Selecting the right clinical trial sites is crucial for the success of first in human biopharma Chile trials, yet many sponsors overlook this vital step. Sponsors should prioritize sites that have a solid understanding of local regulatory frameworks and a proven track record in conducting FIH studies, especially those that are first in human biopharma Chile and governed by the Instituto de Salud Pública (ISP). Engaging with these sites early in the planning phase leads to smoother activation. It opens the door for discussions about demographics, logistical considerations, and resource availability. Utilizing a network of pre-qualified sites can significantly expedite the activation process, reducing the time to first patient in, which typically lasts about 30 days according to industry standards.

    In Latin America, the benefits of conducting studies related to first in human biopharma Chile are substantial, with accelerated ethics approvals often achievable on a timeline set by each committee’s meeting schedule. Make sure that sites are well-staffed and equipped to meet the study’s specific requirements and comply with ICH-GCP standards. Furthermore, sponsors should be aware of the submission routes for approvals, including the necessary documentation and timelines for compliance with the ISP and other relevant authorities such as INVIMA, ANVISA, and COFEPRIS. By concentrating on efficient site selection and activation strategies, sponsors can markedly enhance the overall timeline and success rate of their clinical trials, ultimately leading to faster regulatory approvals and improved patient outcomes.

    This flowchart guides you through the steps to select and activate clinical trial sites effectively. Follow the arrows to see how each step connects to the next, ensuring a smooth process from identifying needs to activating the site.

    Conclusion

    Navigating the complexities of first in human biopharma trials in Chile can be daunting, yet it presents unique opportunities for those who are prepared. A strategic approach is essential, encompassing:

    1. Understanding regulatory frameworks
    2. Conducting early feasibility studies
    3. Implementing effective patient recruitment strategies
    4. Selecting optimal clinical trial sites

    These best practices help streamline the research process. They also position sponsors to leverage Chile’s advantageous clinical landscape, characterized by efficient approval timelines and a growing reputation as a hub for biopharma research in Latin America.

    Key insights from this article highlight the importance of familiarizing oneself with the regulatory environment established by the Instituto de Salud Pública (ISP) and adhering to ICH-GCP standards. Early feasibility studies play a critical role in validating trial designs and ensuring patient safety. Targeted recruitment strategies are essential for achieving enrollment goals. Additionally, the careful selection and activation of clinical trial sites can significantly enhance the speed and success of studies, ultimately leading to faster regulatory approvals and improved patient outcomes.

    In conclusion, the strategic advantages of conducting first in human biopharma trials in Chile cannot be overstated. By embracing these best practices, sponsors can navigate the regulatory landscape more effectively and capitalize on the region’s unique strengths, such as diverse patient populations and rapid approval processes. This proactive approach is key to advancing medical innovation and making sure clinical research in Latin America thrives, ultimately benefiting the global healthcare community.

    Frequently Asked Questions

    What is the importance of understanding regulatory frameworks for first in human (FIH) trials in Chile?

    Understanding the regulatory landscape in Chile is crucial for sponsors to expedite their clinical research efforts, as it allows for efficient navigation of the approval process established by the Instituto de Salud Pública (ISP) and adherence to ICH-GCP standards.

    How long does the approval process for FIH trials typically take in Chile?

    The approval process for FIH trials in Chile typically takes around 30 business days, making it an attractive destination for sponsors seeking expedited timelines.

    What key regulations must sponsors be aware of when conducting FIH trials in Chile?

    Key regulations include Law No. 20.120, which emphasizes the necessity of informed consent and ethical oversight through accredited Scientific Ethics Committees (CECs).

    What are the essential components of a Clinical Trial Application (CTA) for FIH studies in Chile?

    A detailed Clinical Trial Application (CTA) should include thorough study protocols, patient safety measures, and robust data management plans.

    How does familiarity with regulatory guidelines benefit sponsors conducting FIH trials in Chile?

    Familiarity with regulatory guidelines simplifies the approval process and enhances the credibility of study data, which is crucial for subsequent submissions to authorities such as the FDA.

    What is Chile’s current ranking in Latin America regarding research studies as of 2024?

    As of 2024, Chile ranks fourth among Latin American nations for research studies, highlighting its growing importance in the field.

    Why is it essential for sponsors to act swiftly and strategically in Chile’s regulatory environment?

    The shift in research activity towards Chile underscores the need for sponsors to capitalize on the favorable conditions for successful first in human biopharma studies, ensuring they can leverage the country’s advantages in speed, cost efficiency, and patient recruitment.

    List of Sources

    1. Understand Regulatory Frameworks for FIH Trials in Chile
      • Master Regulatory Compliance For Trials In Chile Effectively | bioaccess® (https://bioaccessla.com/blog/master-regulatory-compliance-for-trials-in-chile-effectively)
      • statista.com (https://statista.com/statistics/1560150/chile-number-new-clinical-trials?srsltid=AfmBOooTXyjSwEH4_QafBwJInZYKr08bzEQj6pveus93SvpyjGJzdo9s)
      • Navigate First in Human Medical Device Trials in Chile: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/navigate-first-in-human-medical-device-trials-in-chile-a-step-by-step-guide)
      • bioaccessla.com (https://bioaccessla.com/blog/master-early-phase-clinical-trials-in-chile-key-strategies-and-insights)
    2. Conduct Early Feasibility Studies to Validate Trial Designs
      • inderes.dk (https://inderes.dk/en/articles/probabilities-of-success-in-drug-development)
      • Early feasibility studies on devices: “doing it sooner” to avoid trial failure | Meditrial (https://meditrial.net/2022/09/early-feasibility-studies-on-devices-doing-it-sooner-to-avoid-trial-failure)
      • insights.citeline.com (https://insights.citeline.com/IV154612/Why-Are-Clinical-Development-Success-Rates-Falling)
      • Early Feasibility Studies: Top 6 Considerations | MED Institute (https://medinstitute.com/blog/early-feasibility-studies-top-6-considerations)
    3. Implement Targeted Patient Recruitment Strategies
      • Patient Recruitment and Retention in Clinical Trials: Strategies and Challenges (https://mdgroup.com/blog/patient-recruitment-and-retention-in-clinical-trials-strategies-and-challenges)
      • clariness.com (https://clariness.com/resource/3-patient-recruitment-strategies-in-clinical-trials)
      • Checking your browser – reCAPTCHA (https://pmc.ncbi.nlm.nih.gov/articles/PMC11348161)
      • Latin America: A Compelling Region To Conduct Your Clinical Trials (https://clinicalleader.com/doc/latin-america-a-compelling-region-to-conduct-your-clinical-trials-0001)
      • Patient Recruitment for Clinical Trials: Strategies That Actually Work (https://kapsuletech.com/blog/patient-recruitment-clinical-trials)
    4. Select and Activate Clinical Trial Sites Efficiently
      • Master the Clinical Trial Approval Process in Chile | bioaccess® (https://bioaccessla.com/blog/master-the-clinical-trial-approval-process-in-chile)
      • statista.com (https://statista.com/statistics/1560150/chile-number-new-clinical-trials?srsltid=AfmBOorIgx9EusEA1UXDnMlDFfoY348h5b3ULrkxL-dycroOn2uLWUjd)
      • bioaccessla.com (https://bioaccessla.com/blog/master-early-phase-clinical-trials-in-chile-key-strategies-and-insights)
      • 70 Research Quotes to Inspire Your Work – Qualtrics (https://qualtrics.com/articles/strategy-research/research-quotes)
      • blog.investchile.gob.cl (https://blog.investchile.gob.cl/clinical-trials-investment-in-chile)

  • Master FIH Trials: Key Steps with bioaccess Chile's Expertise

    Master FIH Trials: Key Steps with bioaccess Chile’s Expertise

    Introduction

    First-in-Human (FIH) trials represent a pivotal moment in medical innovation, bridging the gap between theory and practice. With Latin America’s unique regulatory advantages and cost efficiencies, conducting FIH studies in this region presents a golden opportunity for MedTech and Biopharma companies aiming to accelerate their market entry.

    Many organizations struggle to adapt to the regulatory landscape and operational challenges inherent in FIH trials. How can they tap into local expertise to turn these challenges into opportunities?

    This article explores essential steps and strategic insights from bioaccess Chile, guiding companies in transforming potential hurdles into milestones of success.

    Define First-in-Human Trials and Their Importance

    First-in-Human (FIH) studies represent a pivotal moment in clinical research, where the safety and efficacy of new medical devices and pharmaceuticals are put to the test on human subjects for the first time. These evaluations are essential for assessing the safety, tolerability, and pharmacokinetics of investigational products. They play a crucial role in bridging the gap between preclinical studies and later phases, allowing researchers to collect vital data on how humans respond to new therapies.

    In Latin America, the implementation of FIH studies is particularly beneficial due to efficient regulatory pathways and cost savings. Regulatory authorities such as ANVISA in Brazil, COFEPRIS in Mexico, and INVIMA in Colombia facilitate faster approval timelines, often allowing for regulatory decisions within 30 to 90 days. This quick approval process is a game-changer for startups looking to secure funding and move their projects forward without burning through resources.

    Additionally, the expense of executing FIH studies in Latin America can be considerably reduced – up to 30% lower than in conventional markets – while adhering to ICH-GCP standards and ensuring acceptance of FDA-compatible information. This blend of speed and cost-effectiveness establishes Latin America as a strategic center for early-stage studies, allowing innovators to introduce their products to the market more rapidly and effectively.

    As clinical research evolves, how can FIH studies meet the growing demand for timely and reliable data that supports regulatory approvals and market access? By leveraging the advantages of FIH studies in Latin America, companies can not only enhance their chances of success but also redefine the future of clinical research.

    This mindmap starts with the central concept of First-in-Human trials and branches out to show their importance, regulatory advantages, cost benefits, and future implications. Each branch represents a key area of discussion, helping you see how they connect to the main idea.

    Explore bioaccess Chile’s Methodology for FIH Trials

    Navigating the complexities of first-in-human studies can be daunting, but a streamlined approach from bioaccess Chile sets it apart in the Medtech landscape. bioaccess utilizes a comprehensive methodology for conducting FIH studies that includes several key components:

    1. Regulatory Strategy: bioaccess ensures that all studies comply with local regulations and international standards, including ICH-GCP and FDA guidelines. This involves thorough preparation of regulatory submissions to authorities like ANVISA in Brazil and INVIMA in Colombia, which typically see ethics approvals on a timeline set by each committee’s meeting schedule – significantly faster than the 6+ months often required in the US.
    2. Site Selection: The organization employs a network of over 50 pre-qualified clinical study sites across Latin America, ensuring that each location is equipped to meet the specific requirements of FIH studies.
    3. Patient Recruitment: At bioaccess Chile, we focus on engaging diverse patient groups to boost enrollment rates and ensure our studies truly reflect the wider population. This method not only speeds up patient access but also utilizes GCP-compliant information for FDA submissions.
    4. Information Management: The company utilizes sophisticated information management systems to track study progress and ensure integrity, enabling prompt reporting and analysis. This structured approach accelerates assessments and enhances data quality, ensuring fairness and paving the way for more R&D investments.

    Additionally, bioaccess Chile supports early feasibility studies across Colombia, Brazil, and Mexico, further de-risking the development of medical devices. By choosing bioaccess, you’re not just ensuring compliance; you’re investing in a faster, more efficient pathway to market for your innovations.

    This mindmap illustrates the comprehensive methodology used by bioaccess Chile for first-in-human studies. Start at the center with the main methodology, then explore each branch to see the key components and their specific details. Each color-coded branch helps you quickly identify different aspects of the process.

    Implement Key Steps for Successful FIH Trial Execution

    To ensure the success of first-in-human (FIH) trials, sponsors must navigate a series of critical steps that can significantly impact their outcomes:

    1. Conduct Early Feasibility Studies (EFS): Initiate EFS to evaluate the investigational product’s viability in a clinical setting. This step is key because it helps spot potential challenges early and improves the study design. With bioaccess chile, sponsors can utilize our expertise in executing EFS across Colombia, Brazil, and Mexico, ensuring that studies are designed with local insights in mind.
    2. Develop a Comprehensive Protocol: Create a detailed study protocol that clearly outlines objectives, methodologies, and compliance requirements. Have you ever submitted a protocol to regulatory authorities like ANVISA or INVIMA? It’s crucial to ensure compliance with ICH-GCP standards. Bioaccess Chile facilitates this process, helping sponsors navigate the submission pathways efficiently.
    3. Engage with Regulatory Bodies: Maintain proactive communication with regulatory authorities like ANVISA and INVIMA to ensure all requirements are met. This engagement facilitates a smoother approval process and helps navigate the regulatory landscape effectively. With bioaccess chile, sponsors benefit from our established relationships with these regulatory bodies, planning approval timelines around the protocol and each regulator’s review.
    4. Select Qualified Investigators: Choose experienced investigators who are well-versed in FIH studies. Their knowledge is essential for overseeing patient safety and maintaining information integrity throughout the study. Bioaccess Chile assists in identifying and recruiting qualified investigators who comprehend the intricacies of conducting studies in Latin America.
    5. Implement Robust Monitoring Systems: Establish comprehensive monitoring systems to track patient safety, data collection, and compliance with the protocol. This oversight is vital for ensuring the quality and reliability of study results. Bioaccess Chile offers robust monitoring solutions that are customized to the specific needs of first-in-human studies.
    6. Prepare for Analysis: Plan for analysis from the outset, ensuring that statistical methods align with the study design and objectives. This foresight improves the capacity to draw meaningful conclusions from the experimental results. Bioaccess Chile supports sponsors in the development of data analysis plans that comply with regulatory expectations.

    By adhering to these steps, sponsors not only streamline their processes but also enhance their chances of successful outcomes. The strategic benefits of conducting FIH studies in Latin America encompass quicker regulatory approval timelines, cost-effectiveness, and enhanced patient recruitment, establishing it as an optimal region for early-stage research. Ultimately, the right approach can transform the challenges of FIH trials into opportunities for groundbreaking advancements in clinical research.

    Each box represents a crucial step in the process of executing first-in-human trials. Follow the arrows to see how each step leads to the next, ensuring a smooth and successful trial execution.

    Overcome Common Challenges in FIH Trials with bioaccess Solutions

    Navigating the complexities of first-in-human (FIH) studies presents significant hurdles that can impede clinical progress. Common challenges in these studies include:

    1. To tackle regulatory delays, bioaccess chile provides thorough regulatory support, ensuring that all submissions meet the stringent requirements of authorities such as ANVISA and COFEPRIS. This proactive approach can significantly decrease approval timelines, often obtaining regulatory clearance in as little as 30 to 90 days, thanks to our Innovation Runway, specifically designed for FIH studies.
    2. Patient Recruitment Challenges: Have you ever considered that 41% of U.S. adults are unaware of trials? Bioaccess Chile utilizes focused recruitment methods and capitalizes on its vast network of over 50 pre-qualified research sites throughout Latin America to boost patient enrollment. A notable 85% of participants were uninformed about participation options, emphasizing the necessity for effective outreach. Our approach has successfully accelerated recruitment, allowing startups to reach clinical milestones faster.
    3. Implementing robust data management systems that adhere to ICH-GCP standards allows bioaccess chile to maintain data integrity and facilitate timely reporting, reducing the risk of data-related issues.
    4. Site Activation Delays: By utilizing pre-qualified locations and streamlining the site activation process, bioaccess chile ensures that studies can commence quickly, minimizing delays.
    5. Budget overruns can be managed effectively with bioaccess Chile’s cost-efficient model, which includes lower operational costs in Latin America while achieving high-quality results. Additionally, recruitment delays can cost sponsors between $600,000 and $8 million per day, emphasizing the importance of efficient patient recruitment strategies.

    These challenges can result in significant financial implications and extended timelines for clinical trials. By tackling these challenges head-on, bioaccess chile enables sponsors to concentrate on what truly matters and achieve successful trial outcomes. Client testimonials from our partners highlight the effectiveness of our strategies in overcoming these challenges, reinforcing our commitment to accelerating clinical development in Latin America.

    This mindmap illustrates the key challenges in first-in-human trials and how bioaccess Chile addresses each one. Start at the center with the main theme, then explore each branch to see the specific challenges and the innovative solutions provided.

    Conclusion

    Successfully navigating First-in-Human trials is not just a necessity; it’s a strategic imperative for companies aiming to lead in medical innovation. Bioaccess Chile stands at the forefront of this endeavor, offering unique advantages that Latin America provides, including expedited regulatory processes and cost efficiencies. These factors allow companies to accelerate their journey from concept to clinical application, ensuring that their groundbreaking therapies reach the market more swiftly.

    The article highlights several key aspects essential for successful FIH trials:

    1. Early feasibility studies
    2. Comprehensive protocol development
    3. Proactive engagement with regulatory bodies
    4. Selection of qualified investigators

    Bioaccess Chile’s robust methodologies, including effective patient recruitment strategies and advanced data management systems, address common challenges that can hinder progress in clinical research. Achieving regulatory approvals in as little as 30 to 90 days underscores the compelling advantages of conducting trials in Latin America.

    In conclusion, embracing the opportunities presented by FIH trials in Latin America not only enhances the chances of successful outcomes but also fosters innovation within the MedTech and Biopharma sectors. By collaborating with specialized organizations like Bioaccess Chile, sponsors can navigate the complexities of clinical research with confidence. Successfully navigating these trials can position companies as leaders in medical innovation, paving the way for future breakthroughs. The path to medical innovation is paved with the successful execution of FIH trials, and those who seize this opportunity will redefine the future of healthcare.

    Frequently Asked Questions

    What are First-in-Human (FIH) trials?

    First-in-Human (FIH) trials are clinical studies that evaluate the safety and efficacy of new medical devices and pharmaceuticals on human subjects for the first time. These trials are crucial for assessing safety, tolerability, and pharmacokinetics of investigational products.

    Why are FIH trials important in clinical research?

    FIH trials are essential for bridging the gap between preclinical studies and later phases of clinical research. They allow researchers to gather vital data on human responses to new therapies, which is critical for advancing medical innovations.

    How do regulatory authorities in Latin America facilitate FIH trials?

    Regulatory authorities such as ANVISA in Brazil, COFEPRIS in Mexico, and INVIMA in Colombia provide efficient regulatory pathways that enable faster approval timelines, often achieving regulatory decisions within 30 to 90 days.

    What are the cost advantages of conducting FIH trials in Latin America?

    The cost of executing FIH trials in Latin America can be significantly lower-up to 30% compared to conventional markets-while still adhering to ICH-GCP standards and ensuring FDA-compatible information.

    How does the speed of FIH trials in Latin America benefit startups?

    The quick approval process in Latin America allows startups to secure funding and advance their projects more rapidly without depleting their resources, making it a strategic advantage for early-stage clinical trials.

    What compliance standards are necessary for FIH trials in Latin America?

    FIH trials in Latin America must comply with ICH-GCP standards, ensuring that the trials meet international quality and ethical guidelines while also facilitating acceptance of data by the FDA.

    How can companies leverage FIH studies in Latin America for market access?

    By taking advantage of the speed, cost efficiency, and favorable regulatory pathways in Latin America, companies can enhance their chances of success in obtaining timely and reliable data that supports regulatory approvals and market access.

    List of Sources

    1. Define First-in-Human Trials and Their Importance
      • goodreads.com (https://goodreads.com/quotes/tag/medical-research)
      • Clinical Trials Statistics By Phases, Definition and Interventions (2026) (https://media.market.us/clinical-trials-statistics)
      • Beyond the Safety Check: Why First-in-Human Trials Demand a New Approach in 2026 | BioPharm International (https://biopharminternational.com/view/safety-first-human-trials-new-approach)
      • Quotes About Medical Research (https://changingthepresent.org/pages/quotes-about-medical-research)
      • statista.com (https://statista.com/statistics/1249010/clinical-trials-started-by-trial-phase-worldwide?srsltid=AfmBOoqkpLJT831A9DYrCeeIu0Ns5GcxVKUfLGwppVa0RGTrtv9Rd3aa)
    2. Explore bioaccess Chile’s Methodology for FIH Trials
      • Best Practices for First-in-Human Clinical Trials in Brazil | bioaccess® (https://bioaccessla.com/blog/best-practices-for-first-in-human-clinical-trials-in-brazil)
      • linkedin.com (https://linkedin.com/pulse/latin-america-clinical-trials-boom-462b-2025-794b-2034-iaqhc)
      • towardshealthcare.com (https://towardshealthcare.com/insights/latin-america-clinical-trials-market-sizing)
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/latin-america)
    3. Implement Key Steps for Successful FIH Trial Execution
      • goodreads.com (https://goodreads.com/quotes/tag/clinical-trials)
      • jacc.org (https://jacc.org/doi/10.1016/j.jacc.2020.10.019)
      • ahajournals.org (https://ahajournals.org/doi/10.1161/STROKEAHA.122.041650)
      • New York Times Article on Clinical Trials Features Quote from the Alliance for Aging Research – Alliance for Aging Research (https://agingresearch.org/blog/new-york-times-article-on-clinical-trials-features-quote-from-the-alliance-for-aging-research)
      • Quotes About Medical Research (https://changingthepresent.org/pages/quotes-about-medical-research)
    4. Overcome Common Challenges in FIH Trials with bioaccess Solutions
      • Enrollment in Clinical Trials: Statistics and Patient Recruitment Strategies | Power (https://withpower.com/guides/enrollment-in-clinical-trials-statistics-and-patient-recruitment-strategies)
      • What clinical trial statistics tell us about the state of research today (https://antidote.me/blog/what-clinical-trial-statistics-tell-us-about-the-state-of-research-today)
      • SCIRP Open Access (https://scirp.org/journal/paperinformation?paperid=128354)
      • Clinical Trials Statistics By Phases, Definition and Interventions (2026) (https://media.market.us/clinical-trials-statistics)

  • Conducting First-in-Human Clinical Trials in Chile: A Step-by-Step Guide

    Conducting First-in-Human Clinical Trials in Chile: A Step-by-Step Guide

    Introduction

    While Chile offers a promising landscape for first-in-human clinical trials, the path is fraught with challenges that demand careful navigation.

    With its streamlined regulatory processes and robust healthcare infrastructure, Chile stands out as a strategic location for early-stage clinical research.

    However, navigating these complexities can hinder progress and delay trial timelines.

    By understanding these challenges, researchers can turn potential obstacles into strategic advantages.

    Understand Regulatory Requirements for FIH Trials in Chile

    To successfully conduct a first-in-human clinical trial in Chile, understanding the compliance framework is not just beneficial – it’s essential. Here are the essential steps to follow:

    1. Identify Regulatory Authorities: The Instituto de Salud Pública (ISP) is the main regulatory organization supervising clinical studies in Chile. Familiarize yourself with their guidelines and requirements to ensure compliance.
    2. Review Relevant Legislation: Key laws, including Law No. 20.120, govern human research and the Sanitary Code, outlining the ethical and procedural standards necessary for conducting studies.
    3. Prepare Required Documentation: Gather key documents like the clinical study protocol, informed consent forms, and qualifications of your investigators. Ensure all documents comply with ICH-GCP standards to facilitate approval.
    4. Submit to Ethics Committees: Obtain approval from an accredited Scientific Ethics Committee (CEC) before submitting to the ISP. This step is vital for ensuring ethical compliance and safeguarding patient welfare.
    5. Submit Application to ISP: After securing CEC approval, submit your application to the ISP. The review process typically takes about 30 days. Ensure your submission includes all required documentation to prevent delays.
    6. Understand FDA Acceptance: If you plan to submit data to the FDA, ensure your study design aligns with their requirements for acceptance of foreign clinical data under 21 CFR 812.28.

    Navigating the compliance framework can be daunting, especially for first-time researchers involved in the first-in-human clinical trial in Chile. By following these steps, you not only ensure compliance but also enhance the likelihood of a successful study outcome. The ISP’s dedication to regulatory speed and efficiency, along with the country’s robust healthcare infrastructure, establishes it as a strategic advantage for early-stage clinical research.

    Each box represents a step in the process of conducting a first-in-human clinical trial in Chile. Follow the arrows to see how each step leads to the next, ensuring you complete them in order for a successful trial.

    Select and Prepare Clinical Trial Sites in Chile

    Selecting the right clinical research locations is a critical factor that can determine the success of your first-in-human clinical trial in Chile. Here’s a structured approach to ensure effective site selection and preparation:

    1. Identify Potential Locations: Start by recognizing clinical locations with a demonstrated history in FIH studies. Look for facilities that have successfully conducted similar studies and show a track record of compliance and quality outcomes.
    2. Evaluate Location Capabilities: Assess each location’s capabilities, focusing on their infrastructure, staff qualifications, and patient access. Ensure that the location can meet the specific needs of your study protocol, including essential medical equipment and qualified personnel.
    3. Conduct Feasibility Studies: Perform comprehensive feasibility studies to assess the location’s capability to recruit the necessary number of participants within your desired timeline. Understanding local demographics can be challenging, yet it is essential for effective recruitment, especially in a context where Chile has streamlined its clinical study approval processes, reducing bureaucratic delays by over 30% (Instituto de Salud Pública, 2026). Early feasibility studies can further reduce risks in medical device development, allowing for a more informed approach to location selection.
    4. Prepare Location for Testing Execution: After selecting the locations, ready them for testing execution by training staff on the protocol and ensuring adherence to ICH-GCP guidelines. This preparation includes setting up necessary equipment and resources to facilitate smooth operations.
    5. Establish Communication Channels: Create clear communication pathways between the sponsor, staff at the location, and regulatory bodies such as INVIMA. Regular updates and meetings are essential for addressing any issues that may arise during the study, fostering collaboration and commitment.
    6. Monitor Site Readiness: Prior to trial initiation, conduct site visits to confirm that all preparations are complete and that the site is fully equipped to start enrolling participants. This proactive approach helps reduce delays and ensures that you meet industry standards.

    As Julio G. Martinez-Clark, CEO of bioaccess® regulatory, highlights, “In the dynamic landscape of clinical research, navigating the regulatory framework in this region is crucial for success.” By prioritizing strategic site selection and preparation, you position your study as a first-in-human clinical trial in Chile for optimal success in the competitive landscape of clinical research. Moreover, consider the pediatric population, which makes up 30% of the residents in Chile, as an important patient group that could be approached for studies with customized recruitment strategies.

    Each box represents a crucial step in preparing for a clinical trial. Follow the arrows to see how each step leads to the next, ensuring a thorough and organized approach to site selection.

    Implement Effective Patient Recruitment Strategies

    Recruiting patients for first-in-human studies is not just a task; it’s a critical challenge that can determine the success of groundbreaking medical advancements. Effective patient recruitment is essential for the success of your first-in-human (FIH) study. Here are strategies to enhance recruitment efforts, particularly when leveraging bioaccess®’s Innovation Runway:

    1. Leverage Local Networks: Collaborate with local healthcare providers and institutions to identify potential participants. Building relationships with physicians can facilitate referrals, ensuring that you tap into established patient bases. For instance, the FM-TIPS study demonstrated that engaging local providers significantly increased referrals and highlighted the necessity of building trust and communication between researchers and community healthcare professionals.
    2. Utilize Community Engagement: By engaging with the community through informational sessions, health fairs, and local events, you not only raise awareness about the study but also build trust and interest among potential participants. Notably, community engagement efforts have shown that average monthly inquiries across clinics increased from 2.15 inquiries per month prior to engagement to 28.07 inquiries per month after implementing these strategies.
    3. Implement Digital Marketing: Use digital marketing strategies, including social media campaigns and targeted online ads, to reach a broader audience. Emphasize the study’s purpose and potential advantages to generate interest. Successful campaigns have demonstrated significant increases in inquiries and engagement, showcasing the power of online outreach.
    4. Create Patient-Centric Materials: Develop clear and informative resources that describe the study process, potential risks, and benefits. Ensure that these materials are culturally sensitive and available in Spanish to resonate with the local population. This approach aligns with the need for effective communication in diverse communities.
    5. Offer Incentives: Consider providing incentives for participation, such as travel reimbursements or health check-ups. This can inspire individuals to sign up and stay involved throughout the study, addressing potential obstacles to participation. However, it is essential to ensure that compensation is appropriate to avoid perceptions of coercion.
    6. Monitor Recruitment Progress: Regularly assess recruitment metrics to identify any challenges or delays. Adjust strategies as needed to ensure that enrollment targets are met on time. Continuous monitoring allows for timely interventions, enhancing overall recruitment efficiency.

    Without effective recruitment strategies, the potential benefits of innovative treatments may never reach those who need them most. By embracing these strategies, you not only enhance recruitment but also pave the way for innovations, such as those arising from the first-in-human clinical trial in Chile, that could transform patient care in Chile and beyond. Additionally, understanding the regulatory landscape, including the streamlined assessment process outlined in Law 14.874/24, can further capitalize on the region’s unique advantages in speed, cost efficiency, and compliance pathways.

    This mindmap shows various strategies for recruiting patients in clinical studies. Each branch represents a different approach, and you can follow the lines to see how they connect to the main goal of effective recruitment.

    Monitor Trial Progress and Manage Data Effectively

    In the high-stakes environment of the first-in-human clinical trial in Chile, effective monitoring and data management are not just beneficial – they’re essential for success. To ensure effective oversight, consider these critical steps:

    1. Establish Monitoring Plans: Create a detailed monitoring plan that outlines the frequency and methods for overseeing activities, patient safety, and data integrity, aligning with ICH-GCP guidelines.
    2. Utilize Data Management Systems: Implement a robust clinical data management system (CDMS) that streamlines data collection, storage, and analysis while ensuring adherence to standards set by authorities such as ANVISA and COFEPRIS.
    3. Conduct Regular Visits: Schedule frequent visits to assess adherence to the trial protocol and compliance requirements. These visits should also provide support to site staff and address any emerging issues promptly.
    4. Track Patient Safety: Vigilantly monitor patient safety by reviewing adverse event reports and ensuring that all incidents are documented and reported to the relevant oversight bodies, such as INVIMA.
    5. Analyze Data Continuously: Engage in ongoing data analysis to identify trends and potential issues. This proactive approach enables timely interventions and necessary adjustments to the study protocol.
    6. Prepare for Audits: Organize all documentation for easy access during audits by regulatory authorities. This involves maintaining precise records of study activities, patient consent forms, and data entries to ensure compliance and transparency.

    Neglecting these steps could jeopardize not only the trial’s integrity but also patient safety, making adherence to these guidelines imperative.

    Each box represents a step in the process of monitoring and managing data during a clinical trial. Follow the arrows to see the order in which these steps should be taken to ensure success and safety.

    Conclusion

    Navigating first-in-human clinical trials in Chile presents unique challenges that demand a strategic approach. Successfully navigating these trials requires a solid grasp of regulatory frameworks. It also demands strategic site selection, effective patient recruitment, and diligent monitoring of trial progress. By following the outlined step-by-step guide, researchers can streamline their approach, ensuring compliance and maximizing the potential for successful outcomes in this vital phase of clinical research.

    Key insights from this guide emphasize the importance of engaging with regulatory authorities like the Instituto de Salud Pública (ISP) and adhering to ethical standards set by Scientific Ethics Committees. Additionally, selecting appropriate clinical trial sites and employing innovative recruitment strategies are crucial for attracting participants and maintaining momentum throughout the study. Navigating the complex regulatory landscape and ensuring effective patient recruitment can be daunting for researchers. The proactive management of trial data and patient safety monitoring further reinforces the integrity and reliability of the research process.

    Embracing the advantages of conducting first-in-human trials in Chile – such as expedited approval timelines, robust healthcare infrastructure, and a diverse patient population – positions researchers to make significant strides in medical innovation. When stakeholders apply these best practices, they truly help create a thriving clinical research environment that enhances patient care in Chile and sets a model for successful trials across Latin America.

    Frequently Asked Questions

    What is the main regulatory authority for clinical trials in Chile?

    The main regulatory authority supervising clinical studies in Chile is the Instituto de Salud Pública (ISP).

    What key legislation governs human research in Chile?

    Key legislation includes Law No. 20.120 and the Sanitary Code, which outline the ethical and procedural standards necessary for conducting studies.

    What documentation is required to conduct a first-in-human clinical trial in Chile?

    Required documentation includes the clinical study protocol, informed consent forms, and qualifications of investigators, all of which must comply with ICH-GCP standards.

    What is the process for obtaining ethical approval for a clinical trial in Chile?

    Researchers must obtain approval from an accredited Scientific Ethics Committee (CEC) before submitting their application to the ISP. This step is crucial for ensuring ethical compliance and patient welfare.

    How long does the ISP take to review applications for clinical trials?

    The review process typically takes about 30 days once the application is submitted to the ISP.

    What should be considered if planning to submit data to the FDA?

    If planning to submit data to the FDA, ensure that the study design aligns with their requirements for acceptance of foreign clinical data under 21 CFR 812.28.

    Why is understanding the compliance framework essential for first-in-human trials in Chile?

    Understanding the compliance framework is essential to ensure regulatory adherence, enhance the likelihood of a successful study outcome, and navigate the complexities of conducting clinical trials in Chile effectively.

    What advantages does Chile offer for early-stage clinical research?

    Chile offers advantages such as regulatory speed and efficiency, a robust healthcare infrastructure, and cost-effective patient recruitment, making it a strategic location for early-stage clinical trials.

    List of Sources

    1. Understand Regulatory Requirements for FIH Trials in Chile
      • Chile Clinical Trial Regulations | ISP Guide | bioaccess® (https://bioaccessla.com/regulatory-guide/chile)
      • Master the Clinical Trial Approval Process in Chile | bioaccess® (https://bioaccessla.com/blog/master-the-clinical-trial-approval-process-in-chile)
      • First-in-Human Medical Device Trial in Chile | bioaccess® (https://bioaccessla.com/blog/first-in-human-medical-device-trial-chile)
      • pharmaregulatory.in (https://pharmaregulatory.in/country-specific-regulatory-affairs/chile-isp-instituto-de-salud-publica)
      • Master Regulatory Compliance For Trials In Chile Effectively | bioaccess® (https://bioaccessla.com/blog/master-regulatory-compliance-for-trials-in-chile-effectively)
    2. Select and Prepare Clinical Trial Sites in Chile
      • bioaccessla.com (https://bioaccessla.com/blog/clinical-trial-site-selection-latin-america-key-strategies)
      • Master Regulatory Compliance For Trials In Chile Effectively | bioaccess® (https://bioaccessla.com/blog/master-regulatory-compliance-for-trials-in-chile-effectively)
      • reedintelligence.com (https://reedintelligence.com/market-analysis/chile-first-in-human-clinical-trial-market)
      • noymed.com (https://noymed.com/~noymedco/conducting-site-selection-the-key-factors-and-strategies-in-site-selection-for-clinical-trials)
      • Clinical Trial Site Selection: Key Challenges & Solutions for Phase 3 Success (https://precisionformedicine.com/blog/clinical-trial-site-selection-key-challenges-solutions-for-phase-3-success)
    3. Implement Effective Patient Recruitment Strategies
      • Community engagement is key to clinical trial recruitment and diversity (https://statnews.com/2019/08/23/clinical-trial-recruitment-diversity-community-engagement)
      • Improving Recruitment Through Community Engagement (https://clinicalleader.com/doc/improving-recruitment-through-community-engagement-0001)
      • Checking your browser – reCAPTCHA (https://pmc.ncbi.nlm.nih.gov/articles/PMC12444702)
      • Latin America: A Compelling Region To Conduct Your Clinical Trials (https://clinicalleader.com/doc/latin-america-a-compelling-region-to-conduct-your-clinical-trials-0001)
      • 10 Inspiring Patient Experience Quotes | Relias (https://relias.com/blog/patient-experience-quotes)
    4. Monitor Trial Progress and Manage Data Effectively
      • usnews.com (https://usnews.com/news/us/articles/2026-04-28/us-fda-to-monitor-clinical-trial-data-in-real-time-in-pilot-program-aimed-at-speeding-approvals)
      • Quotes Related to Data and Data Governance (https://blog.idatainc.com/quotes-related-to-data-and-data-governance)
      • drugs.com (https://drugs.com/news/fda-moves-real-time-clinical-trial-patient-monitoring-faster-review-129839.html)
      • pipeline.zoominfo.com (https://pipeline.zoominfo.com/operations/19-inspirational-quotes-about-data)
      • Importance of Clinical Data Management in Clinical Trials (https://sofpromed.com/importance-of-clinical-data-management-in-clinical-trials)

  • Master FIH Clinical Trials in Chile: A Step-by-Step Guide

    Master FIH Clinical Trials in Chile: A Step-by-Step Guide

    Introduction

    Researchers face a daunting landscape when it comes to first-in-human (FIH) clinical trials in Chile, where both challenges and opportunities abound. The regulatory landscape, shaped by the Instituto de Salud Pública (ISP), along with a growing network of compliant sites, can feel overwhelming, but knowing the right steps can lead to successful trial execution.

    What strategies can researchers employ to navigate the intricacies of compliance, patient recruitment, and data management, ensuring their studies reach their full potential and bring innovative therapies to market faster?

    Understand the Regulatory Landscape for FIH Trials in Chile

    Navigating the regulatory landscape for the FIH clinical trial Chile can be daunting, yet it is crucial for successful clinical research. Understanding the regulatory framework established by the Instituto de Salud Pública (ISP) is essential. Here are the key steps:

    1. Familiarize Yourself with Relevant Laws: Review Law No. 20,120, which governs human research in Chile. This law establishes the ethical and scientific standards necessary for clinical evaluations, ensuring participant safety and data integrity.
    2. Identify Necessary Endorsements: Acquire required endorsements from the ISP by presenting a detailed study protocol outlining the objectives, methodology, and ethical considerations of the investigation. This step is crucial for compliance and successful trial execution.
    3. Understand Submission Timelines: The authorization process typically spans 30 to 60 days. Preparing your documentation in advance can help mitigate delays and streamline the review process.
    4. Engage with Local Ethics Committees: Collaborate with accredited ethics committees to ensure your study adheres to ethical standards. This engagement is crucial for obtaining the necessary permissions and ensuring compliance throughout the study.
    5. Prepare for Compliance Audits: Be ready for potential audits by the ISP or ethics committees. Ensure that all study documentation is thorough and complies with ICH-GCP guidelines, which are critical for maintaining the integrity of your research.

    By mastering these compliance aspects, you not only pave the way for your study’s success but also position yourself to capitalize on the unique opportunities within the FIH clinical trial Chile. Furthermore, consider subscribing to bioaccess®’s clinical insights service, which offers valuable updates on regulatory changes and market access strategies, enhancing your ability to leverage the region’s strategic advantages in speed and cost efficiency.

    Each box represents a step you need to take in the regulatory process for clinical trials. Follow the arrows to see how each step leads to the next, ensuring you cover all necessary actions for compliance.

    Select Sites and Recruit Patients Effectively

    Navigating the complexities of the FIH clinical trial in Chile requires strategic site selection and effective participant recruitment. Follow these steps to ensure success:

    1. Identify Potential Sites: Concentrate on clinical locations with demonstrated experience in FIH studies and a robust compliance record with ICH-GCP standards. Leverage bioaccess®’s extensive network of pre-qualified sites to streamline your selection process.
    2. Evaluate Site Capabilities: Assess each site’s infrastructure, ensuring access to necessary medical equipment and qualified staff. Confirm that they can meet the specific demands of your study, including surgical capabilities and procurement flexibility.
    3. Engage Local Investigators: Collaborate with local principal investigators who have established relationships within the patient community. Their insights and connections can significantly enhance recruitment efforts and build patient trust.
    4. Develop a Patient Recruitment Strategy: Create a comprehensive recruitment plan that includes outreach to local healthcare providers, community organizations, and online platforms. Tailor your messaging to resonate with potential participants, emphasizing the benefits of participation.
    5. Utilize Digital Tools: Leverage digital marketing and social media to broaden your reach. Consider using patient registries and databases to identify eligible candidates efficiently, enhancing your recruitment pool.
    6. Monitor Recruitment Progress: Regularly track recruitment metrics and adjust your strategies as necessary to ensure you meet enrollment targets within the planned timelines. This proactive strategy can assist in reducing delays frequently faced in clinical studies.

    Implementing these strategies is crucial. Without them, the risk of delays and regulatory challenges in your FIH study could significantly increase.

    Each box represents a step in the process of selecting sites and recruiting patients for clinical trials. Follow the arrows to see how each step connects to the next, guiding you through the entire recruitment strategy.

    Execute the Trial: Manage Timelines and Monitor Progress

    Successfully executing a FIH clinical trial in Chile requires not just planning, but a strategic approach to overcome inherent challenges. Here’s how to effectively manage timelines and monitor progress:

    1. Develop a Detailed Project Timeline: Create a comprehensive timeline that outlines all phases of the study, including site activation, patient enrollment, and data collection. Use project management tools to visualize progress. This ensures alignment with regulatory timelines set by authorities like ANVISA or COFEPRIS, which typically offer ethics approvals on a timeline set by each committee’s meeting schedule-far quicker than the 6+ months often required in the US.
    2. Establish Clear Milestones: Set specific milestones for each phase of the study. This approach facilitates tracking progress and allows for early identification of potential delays, ensuring that the study adheres to the 12-month protocol-to-LPLV execution timeline. As indicated by a clinical study project manager, “Establishing clear milestones is vital for sustaining momentum and ensuring accountability within the team.”
    3. Conduct Regular Team Meetings: Schedule frequent meetings with your clinical operations team to discuss progress, address challenges, and adjust timelines as necessary. Keeping the lines of communication open helps the team stay aligned and respond quickly to any issues that pop up.
    4. Implement Monitoring Protocols: Utilize real-time monitoring tools to track patient enrollment and information collection. This proactive approach enables quick identification of issues, ensuring that recruitment remains on target and compliant with ICH-GCP standards. For example, a diabetes study achieved a 95% retention rate by incorporating innovative monitoring methods, demonstrating the effectiveness of such tools.
    5. Ensure Compliance with Regulatory Requirements: Regularly review compliance with ICH-GCP guidelines and local regulations. Conduct internal audits to ensure that all experimental activities are documented and meet the stringent standards required for FDA-bridgeable data acceptance. Comprehending the specific needs of regulatory agencies such as ANVISA and COFEPRIS is crucial for successful execution of studies.
    6. Prepare for Interim Analysis: Plan for interim evaluations to assess the study’s progress. This enables well-informed choices about the continuation, alteration, or halt of the study based on the gathered data, enhancing resource allocation and efficiency.

    By adhering to these steps, you can efficiently oversee your FIH clinical trial in Chile, ensuring that it stays on track and meets all compliance standards. Embracing these strategies not only enhances your study’s efficiency but also positions your innovative therapies for a faster market entry, ultimately benefiting patients in need.

    This flowchart outlines the key steps to effectively manage a clinical trial. Each box represents a crucial action, and the arrows show how each step leads to the next. Follow the flow to understand how to keep your trial on track and compliant.

    Manage Data and Prepare for Regulatory Submissions

    Navigating the complexities of compliance submissions is crucial for the success of your FIH clinical trial in Chile. Here’s how to ensure these processes are handled efficiently:

    1. Establish a Management Plan (MP): Develop a comprehensive MP that details how information will be collected, stored, and analyzed, ensuring compliance with ICH-GCP guidelines and local regulations such as those set by INVIMA in Colombia or ANVISA in Brazil. This plan should also outline specific timelines for regulatory approvals, which can be significantly faster in Latin America compared to other regions, leveraging insights from Global Trial Accelerators™.
    2. Utilize Electronic Capture Systems: Implement EDC systems to streamline information collection and minimize errors. These systems enhance information quality by permitting real-time input and validation, significantly reducing the risk of human error. As Carlos Verdú, a Clinical Data Manager, states, “EDC systems enable quicker information processing and enhance compliance with regulations by ensuring clean, complete datasets.”
    3. Conduct Regular Quality Checks: Perform routine assessments to ensure integrity and accuracy. Address any inconsistencies promptly to maintain high-quality information, which is essential for compliance submissions and overall trial success.
    4. Prepare Submission Documents: Compile all necessary documentation for submissions to authorities, including study protocols, informed consent forms, and data analysis reports. Ensure that these documents meet the requirements set by local governing bodies, such as the ISP in Chile, to facilitate a smoother review process.
    5. Engage with Oversight Bodies Early: Maintain open communication with oversight entities throughout the submission process. Early engagement can clarify questions and expedite the review process, which is critical in fast-paced environments like Latin America. Understanding the specific compliance requirements and authorization timelines can greatly improve your submission strategy, as emphasized by the Global Trial Accelerators™ insights.
    6. Plan for Post-Submission Follow-Up: After submission, be prepared to respond promptly to any inquiries from oversight authorities. Taking this proactive approach helps ensure a smoother approval process and keeps your clinical study timeline on track.

    By effectively managing data and preparing for regulatory submissions, you enhance the likelihood of a successful outcome for the FIH clinical trial in Chile, leveraging the region’s strategic advantages in speed, cost efficiency, and patient recruitment, as emphasized by bioaccess®.

    Each box represents a step in the process of preparing for regulatory submissions. Follow the arrows to see how each step leads to the next, ensuring a smooth and efficient submission process.

    Conclusion

    Navigating the first-in-human (FIH) clinical trial landscape in Chile presents unique challenges that demand a strategic approach to regulatory compliance and patient engagement. Successfully addressing these challenges requires a comprehensive understanding of regulatory requirements, effective site selection, and robust patient recruitment strategies. Mastering these elements significantly enhances researchers’ chances of conducting successful trials, capitalizing on Latin America’s advantages in speed, cost efficiency, and patient access.

    This guide outlines key steps, highlighting the need to familiarize with local regulations like Law No. 20,120 and engage with ethics committees for compliance. Additionally, strategic site selection and innovative recruitment tactics play crucial roles in minimizing delays and optimizing enrollment. Implementing detailed project management practices and utilizing electronic data capture systems further streamline the trial process, ensuring adherence to ICH-GCP standards and enhancing data integrity.

    The potential for successful FIH clinical trials in Chile is immense, driven by the region’s regulatory efficiency and access to diverse patient populations. The commitment to these strategies not only accelerates timelines but also positions researchers at the forefront of medical innovation, ultimately transforming patient care in the region.

    Frequently Asked Questions

    What is the primary law governing human research in Chile?

    The primary law governing human research in Chile is Law No. 20,120, which establishes the ethical and scientific standards necessary for clinical evaluations, ensuring participant safety and data integrity.

    What are the necessary endorsements required for conducting a FIH trial in Chile?

    Necessary endorsements include acquiring approval from the Instituto de Salud Pública (ISP) by submitting a detailed study protocol that outlines the objectives, methodology, and ethical considerations of the investigation.

    How long does the authorization process typically take for FIH trials in Chile?

    The authorization process typically spans 30 to 60 days. Preparing documentation in advance can help mitigate delays and streamline the review process.

    Why is it important to engage with local ethics committees when conducting clinical trials in Chile?

    Engaging with accredited ethics committees is crucial to ensure that the study adheres to ethical standards, which is necessary for obtaining the required permissions and maintaining compliance throughout the study.

    What should researchers be prepared for regarding compliance audits in Chile?

    Researchers should be prepared for potential audits by the ISP or ethics committees and ensure that all study documentation is thorough and complies with ICH-GCP guidelines to maintain the integrity of the research.

    How can subscribing to bioaccess®’s clinical insights service benefit researchers conducting FIH trials in Chile?

    Subscribing to bioaccess®’s clinical insights service provides valuable updates on regulatory changes and market access strategies, enhancing researchers’ ability to leverage the region’s strategic advantages in speed and cost efficiency for their trials.

    List of Sources

    1. Understand the Regulatory Landscape for FIH Trials in Chile
      • Master Regulatory Compliance For Trials In Chile Effectively | bioaccess® (https://bioaccessla.com/blog/master-regulatory-compliance-for-trials-in-chile-effectively)
      • pharmexec.com (https://pharmexec.com/view/country-report-chile)
    2. Select Sites and Recruit Patients Effectively
      • First-in-Human Medical Device Trial in Chile | bioaccess® (https://bioaccessla.com/blog/first-in-human-medical-device-trial-chile)
      • 2025 Trends In Patient Recruitment: From Disruption To Precision (https://clinicalleader.com/doc/trends-in-patient-recruitment-from-disruption-to-precision-0001)
      • goodreads.com (https://goodreads.com/quotes/tag/clinical-trials)
      • 10 Inspiring Patient Experience Quotes | Relias (https://relias.com/blog/patient-experience-quotes)
      • gcihealth.com (https://gcihealth.com/2026/01/22/precision-relevance-and-prediction-the-future-of-clinical-trial-recruitment)
    3. Execute the Trial: Manage Timelines and Monitor Progress
      • 25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)
      • 35 Best Project Management Quotes (https://projectmanager.com/blog/10-best-project-management-quotes)
      • Enrollment and Retention: A Strategic Imperative for Clinical Trial Success – Confidence Pharmaceutical Research (https://confidenceresearch.com/enrollment-and-retention-a-strategic-imperative-for-clinical-trial-success)
      • The 62 Most Inspiring Project Management Quotes (https://inloox.com/company/blog/articles/the-62-most-inspiring-project-management-quotes)
    4. Manage Data and Prepare for Regulatory Submissions
      • Paving the Path to Success Through Effective Clinical Trial Data Management (https://namsa.com/resources/blog/effective-clinical-trial-data-management)
      • Electronic Data Capture (EDC) Systems Explained (https://ccrps.org/clinical-research-blog/electronic-data-capture-edc-systems)
      • 8 key benefits of electronic data capture for clinical trials | Viedoc (https://viedoc.com/blog/key-benefits-electronic-data-capture-clinical-trials)
      • The Ultimate Guide to Electronic Data Capture for Clinical Trials (https://quanticate.com/blog/electronic-data-capture-systems-in-clinical-trials)
      • datascience.codata.org (https://datascience.codata.org/articles/dsj-2023-002)